1
|
Garabano G, Pesciallo CA, Rodriguez J, Perez Alamino L, Tillet F, Del Sel H, Lopreite F. Early appearance of radiolucent lines around total knee arthroplasty in rheumatoid arthritis patients. How does it impact the aseptic failure rate and functional outcomes at 13 years of follow-up? Rev Esp Cir Ortop Traumatol (Engl Ed) 2024; 68:239-246. [PMID: 37315920 DOI: 10.1016/j.recot.2023.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 05/30/2023] [Accepted: 06/07/2023] [Indexed: 06/16/2023] Open
Abstract
INTRODUCTION Aseptic total knee arthroplasty (TKA) failure has been associated with radiolucent lines. This study aimed to determine the impact of the early appearance of radiolucent lines (linear images of 1, 2, or >2mm at the cement-bone interface) around the TKA on prosthetic survival and functional outcomes in rheumatoid arthritis (RA) patients during a 2-20 years follow-up. METHODS We retrospectively analyzed a consecutive series of RA patients treated with TKA between 2000 and 2011. We comparatively analyzed patients with and without radiolucent lines around implants. Clinical outcomes were assessed with the knee society score (KSS) collected before surgery, at years 2, 5, and 10, and at the last postoperative follow-up. The knee society roentgenographic evaluation system was used to analyze the impact of radiolucent lines around the implants at 1, 2, 5, and more than ten years of follow-up. The reoperation and prosthetic survival rates were calculated at the end of the follow-up. RESULTS The study series included 72 TKAs with a median follow-up of 13.2 years (range: 4.0-21.0), of which 16 (22.2%) had radiolucent lines. We did not observe aseptic failure, and prosthetic survival at the end of the study was 94.4% (n=68). The KSS improved significantly (p<0.001) between preoperative values at 2, 5, and 10 years and the end of follow-up, with no differences between patients with and without radiolucent lines. CONCLUSIONS Our study demonstrates that the early appearance of radiolucent lines around a TKA in RA patients does not significantly impact prosthetic survival or long-term functional outcomes at 13 years of follow-up.
Collapse
Affiliation(s)
- G Garabano
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina.
| | - C A Pesciallo
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina
| | - J Rodriguez
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina
| | - L Perez Alamino
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina
| | - F Tillet
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina
| | - H Del Sel
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina
| | - F Lopreite
- Department of Orthopaedic and Traumatology, British Hospital of Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
2
|
Garabano G, Pesciallo CA, Rodríguez J, Pérez Alamino L, Tillet F, Del Sel H, Lopreite F. Early appearance of radiolucent lines around total knee arthroplasty in rheumatoid arthritis patients. How does it impact the aseptic failure rate and functional outcomes at 13 years of follow-up? Rev Esp Cir Ortop Traumatol (Engl Ed) 2024; 68:T239-T246. [PMID: 38232933 DOI: 10.1016/j.recot.2024.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 06/07/2023] [Indexed: 01/19/2024] Open
Abstract
INTRODUCTION Aseptic total knee arthroplasty (TKA) failure has been associated with radiolucent lines. This study aimed to determine the impact of the early appearance of radiolucent lines (linear images of 1, 2, or > 2mm at the cement-bone interface) around the TKA on prosthetic survival and functional outcomes in rheumatoid arthritis (RA) patients during a 2-20 years follow-up. METHODS We retrospectively analyzed a consecutive series of RA patients treated with TKA between 2000 and 2011. We comparatively analyzed patients with and without radiolucent lines around implants. Clinical outcomes were assessed with the knee society score (KSS) collected before surgery, at years 2, 5, and 10, and at the last postoperative follow-up. The knee society roentgenographic evaluation system was used to analyze the impact of radiolucent lines around the implants at 1, 2, 5, and more than ten years of follow-up. The reoperation and prosthetic survival rates were calculated at the end of the follow-up. RESULTS The study series included 72 TKAs with a median follow-up of 13.2 years (range: 4.0-21.0), of which 16 (22.2%) had radiolucent lines. We did not observe aseptic failure, and prosthetic survival at the end of the study was 94.4% (n=68). The KSS improved significantly (p<0.001) between preoperative values at 2, 5, and 10 years and the end of follow-up, with no differences between patients with and without radiolucent lines. CONCLUSIONS Our study demonstrates that the early appearance of radiolucent lines around a TKA in RA patients does not significantly impact prosthetic survival or long-term functional outcomes at 13 years of follow-up.
Collapse
Affiliation(s)
- G Garabano
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
| | - C A Pesciallo
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
| | - J Rodríguez
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
| | - L Pérez Alamino
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
| | - F Tillet
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
| | - H Del Sel
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
| | - F Lopreite
- Departamento de Traumatología y Ortopedia, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
3
|
Zhang AR, Cheng QH, Yang YZ, Yang X, Zhang ZZ, Guo HZ. Meta-analysis of outcomes after total knee arthroplasty in patients with rheumatoid arthritis and osteoarthritis. Asian J Surg 2024; 47:43-54. [PMID: 37777403 DOI: 10.1016/j.asjsur.2023.09.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 08/27/2023] [Accepted: 09/06/2023] [Indexed: 10/02/2023] Open
Abstract
The purpose of this study was to compare the difference in functional scores and the incidence of complications after TKA between RA and osteoarthritis. The PubMed, MedLine, The Cochrane Library, Embase and Web of Science databases were searched for all clinical studies up to 15 March 2023 comparing outcomes after total knee replacement in patients with RA and OA, with two review authors independently screening the literature. A total of 7,820,115 (knee-counted) cases were included in 34 studies. The results of meta-analysis showed that the scores of the RA group were lower than that of the osteoarthritis group in the postoperative knee joint score [MD=-2.72,95%CI(-5.06,-0.38),P=0.02] and the postoperative knee joint function score [MD=-11.47,95%CI(-16.55,-6.39),P<0.00001], and the difference was statistically significant. The incidence of deep venous thrombosis (OR=0.84,95%CI(0.79,0.90),P<0.00001) and pulmonary embolism (OR=0.84,95%CI(0.78,0.91),P<0.00001) were significantly lower in RA than in osteoarthritis (P<0.00001). Compared with patients with osteoarthritis, patients with rheumatoid arthritis have lower knee society scores and functional scores after total knee arthroplasty, and a higher risk of prosthetic infection, loosening, and revision, but TKA can still effectively reduce pain in RA patients, Improve function and quality of life without increasing the risk of lower extremity venous thrombosis and pulmonary embolism. Therefore, total knee replacement can be used as a treatment option for patients with rheumatoid arthritis who have not responded to conservative treatment. Patients should fully understand the benefits and possible risks of total knee replacement and develop an individualized treatment plan.
Collapse
Affiliation(s)
- An-Ren Zhang
- First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, China; Gansu Provincial Hospital, Lanzhou, China.
| | | | - Yong-Ze Yang
- First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, China; Gansu Provincial Hospital, Lanzhou, China
| | - Xin Yang
- First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, China; Gansu Provincial Hospital, Lanzhou, China
| | - Zhuang-Zhuang Zhang
- First Clinical Medical College of Gansu University of Traditional Chinese Medicine, Lanzhou, China; Gansu Provincial Hospital, Lanzhou, China
| | | |
Collapse
|
4
|
Eberhard A, Rydell E, Forslind K, Bergman S, Mandl T, Olofsson T, Jacobsson LTH, Turesson C. Radiographic damage in early rheumatoid arthritis is associated with increased disability but not with pain-a 5-year follow-up study. Arthritis Res Ther 2023; 25:29. [PMID: 36849881 PMCID: PMC9969673 DOI: 10.1186/s13075-023-03015-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2023] [Accepted: 02/15/2023] [Indexed: 03/01/2023] Open
Abstract
OBJECTIVES To evaluate how radiographic damage, overall and measured as joint space narrowing score (JSNS) and erosion score (ES), as well as other clinical and laboratory measures, relate to disability and pain in early rheumatoid arthritis (RA). METHODS An inception cohort of 233 patients with early RA, recruited in 1995-2005, was followed for 5 years. Disability was assessed with the Health Assessment Questionnaire (HAQ), and pain with a visual analogue scale (VAS; 0-100 mm). Radiographs of hands and feet were evaluated using the Sharp-van der Heijde score (SHS), including JSNS and ES. The relation for radiographic scores and other clinical parameters with pain and HAQ were evaluated cross-sectionally by multivariate linear regression analysis and over time using generalized estimating equations. RESULTS ES was significantly associated with HAQ cross-sectionally at inclusion, after 2 and after 5 years, and over time. Associations for HAQ with SHS and JSNS were weaker and less consistent compared with those for ES. There was no association between radiographic scores and pain at any visit. Both HAQ and pain were associated with parameters of disease activity. The strongest cross-sectional associations were found for the number of tender joints (adjusted p<0.001 at all visits). CONCLUSION Joint damage was associated with disability already in early RA. Erosions of hands and feet appear to have a greater influence on disability compared with joint space narrowing early in the disease. Pain was associated with other factors than joint destruction in early RA, in particular joint tenderness-suggesting an impact of pain sensitization.
Collapse
Affiliation(s)
- Anna Eberhard
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1b, 205 02, Malmö, Sweden. .,Helsingborg Hospital, Helsingborg, Sweden.
| | - Emil Rydell
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1b, 205 02, Malmö, Sweden
| | - Kristina Forslind
- Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.,Spenshult Research and Development Center, Halmstad, Sweden
| | - Stefan Bergman
- Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.,Spenshult Research and Development Center, Halmstad, Sweden.,Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Thomas Mandl
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1b, 205 02, Malmö, Sweden
| | - Tor Olofsson
- Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| | - Lennart T H Jacobsson
- Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg, Sweden
| | - Carl Turesson
- Rheumatology, Department of Clinical Sciences Malmö, Lund University, Jan Waldenströms gata 1b, 205 02, Malmö, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
5
|
Singh H, Tanwar V, Kalra A, Saini A, Arora S, Govil N. Implication and utility of DAS-28 squeeze in rheumatoid arthritis: an Indian experience. Reumatismo 2022; 74. [PMID: 36101988 DOI: 10.4081/reumatismo.2022.1501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 08/10/2022] [Indexed: 11/22/2022] Open
Abstract
The purpose of this study was to compare and correlate disease activity score including 28 joints counts (DAS-28) Squeeze with DAS-28 and clinical disease activity index (CDAI) to assess disease activity (DA) in rheumatoid arthritis (RA) patients. A total of 100 RA patients were included in the study. All subjects were evaluated for disease activity using the DAS-28 Squeeze, DAS-28, and CDAI. Spearman’s rho (ρ) was calculated to determine the correlation between DAS-28 Squeeze, DAS-28, and CDAI. Cross-tabulation was performed to compare and calculate the kappa coefficient for the link between two indices. For each scale, Cronbach’s alpha was also calculated to test dependability. The average age of the study group was 43.9±11.3. The mean scores on the DAS-28 Squeeze, DAS-28, and CDAI were, respectively, 3.58±1.06, 5.06±1.56, and 22.81±14.92. p=0.001 indicated a significant correlation between DAS-28 Squeeze and DAS-28 (ρ=0.986) and CDAI (ρ=0.939) for DAS-28 Squeeze. There was a considerable correlation between all three measures at various DA levels. Cronbach’s alpha for DAS-28 Squeeze, DAS-28, and CDAI were respectively 0.716, 0.663, and 0.734. DAS-28 Squeeze exhibited a substantial positive association with DAS-28 and CDAI for assessing disease activity and appears to be a more useful and reliable method than DAS-28 and CDAI for monitoring disease activity in RA patients.
Collapse
|
6
|
Kronzer VL, Crowson CS, Davis JM, Vassilaki M, Mielke MM, Myasoedova E. Trends in incidence of dementia among patients with rheumatoid arthritis: A population-based cohort study. Semin Arthritis Rheum 2021; 51:853-857. [PMID: 34174733 PMCID: PMC8384708 DOI: 10.1016/j.semarthrit.2021.06.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 05/12/2021] [Accepted: 06/10/2021] [Indexed: 10/21/2022]
Abstract
OBJECTIVE We aimed to assess the incidence of dementia over time in patients with incident rheumatoid arthritis (RA) as compared to non-RA referents. METHODS This population-based, retrospective cohort study included Olmsted County, Minnesota residents with incident RA by ACR 1987 criteria, diagnosed between 1980 and 2009. We matched non-RA referents 1:1 on age, sex, and calendar year and followed all individuals until 12/31/2019. Incident dementia was defined as two codes for Alzheimer's disease and related dementias (ADRD) at least 30 days apart. Cumulative incidence of ADRD was assessed, adjusting for the competing risk of death. Cox proportional hazards models calculated hazard ratios (HR) with 95% confidence intervals (CI) for incident ADRD by decade. RESULTS After excluding individuals with prior dementia, we included 897 persons with incident RA (mean age 56 years; 69% female) and 885 referents. The 10-year cumulative incidence of ADRD in individuals diagnosed with RA during the 1980s was 12.7% (95%CI:7.9-15.7%), 1990s was 7.2% (95%CI:3.7-9.4%), and 2000s was 6.2% (95%CI:3.6-7.8%). Individuals with RA diagnosed in 2000s had insignificantly lower cumulative incidence of ADRD than those in the 1980s (HR 0.66; 95%CI:0.38-1.16). The overall HR of ADRD in individuals with RA was 1.37 (vs. referents; 95%CI:1.04-1.81). When subdivided by decade, however, the risk of ADRD in individuals diagnosed with RA was higher than referents in the 1990s (HR 1.72, 95%CI:1.09-2.70) but not 2000s (HR 0.86, 95%CI:0.51-1.45). CONCLUSIONS The risk of dementia in individuals with RA appears to be declining over time, including when compared to general population referents.
Collapse
Affiliation(s)
| | - Cynthia S Crowson
- Division of Rheumatology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
| | - John M Davis
- Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
| | - Maria Vassilaki
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
| | - Michelle M Mielke
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | - Elena Myasoedova
- Division of Rheumatology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
| |
Collapse
|
7
|
Scott DL, Ibrahim F, Hill H, Tom B, Prothero L, Baggott RR, Bosworth A, Galloway JB, Georgopoulou S, Martin N, Neatrour I, Nikiphorou E, Sturt J, Wailoo A, Williams FMK, Williams R, Lempp H. Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. PROGRAMME GRANTS FOR APPLIED RESEARCH 2021. [DOI: 10.3310/pgfar09080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background
Rheumatoid arthritis is a major inflammatory disorder and causes substantial disability. Treatment goals span minimising disease activity, achieving remission and decreasing disability. In active rheumatoid arthritis, intensive management achieves these goals. As many patients with established rheumatoid arthritis have moderate disease activity, the TITRATE (Treatment Intensities and Targets in Rheumatoid Arthritis ThErapy) programme assessed the benefits of intensive management.
Objectives
To (1) define how to deliver intensive therapy in moderate established rheumatoid arthritis; (2) establish its clinical effectiveness and cost-effectiveness in a trial; and (3) evaluate evidence supporting intensive management in observational studies and completed trials.
Design
Observational studies, secondary analyses of completed trials and systematic reviews assessed existing evidence about intensive management. Qualitative research, patient workshops and systematic reviews defined how to deliver it. The trial assessed its clinical effectiveness and cost-effectiveness in moderate established rheumatoid arthritis.
Setting
Observational studies (in three London centres) involved 3167 patients. These were supplemented by secondary analyses of three previously completed trials (in centres across all English regions), involving 668 patients. Qualitative studies assessed expectations (nine patients in four London centres) and experiences of intensive management (15 patients in 10 centres across England). The main clinical trial enrolled 335 patients with diverse socioeconomic deprivation and ethnicity (in 39 centres across all English regions).
Participants
Patients with established moderately active rheumatoid arthritis receiving conventional disease-modifying drugs.
Interventions
Intensive management used combinations of conventional disease-modifying drugs, biologics (particularly tumour necrosis factor inhibitors) and depot steroid injections; nurses saw patients monthly, adjusted treatment and provided supportive person-centred psychoeducation. Control patients received standard care.
Main outcome measures
Disease Activity Score for 28 joints based on the erythrocyte sedimentation rate (DAS28-ESR)-categorised patients (active to remission). Remission (DAS28-ESR < 2.60) was the treatment target. Other outcomes included fatigue (measured on a 100-mm visual analogue scale), disability (as measured on the Health Assessment Questionnaire), harms and resource use for economic assessments.
Results
Evaluation of existing evidence for intensive rheumatoid arthritis management showed the following. First, in observational studies, DAS28-ESR scores decreased over 10–20 years, whereas remissions and treatment intensities increased. Second, in systematic reviews of published trials, all intensive management strategies increased remissions. Finally, patients with high disability scores had fewer remissions. Qualitative studies of rheumatoid arthritis patients, workshops and systematic reviews helped develop an intensive management pathway. A 2-day training session for rheumatology practitioners explained its use, including motivational interviewing techniques and patient handbooks. The trial screened 459 patients and randomised 335 patients (168 patients received intensive management and 167 patients received standard care). A total of 303 patients provided 12-month outcome data. Intention-to-treat analysis showed intensive management increased DAS28-ESR 12-month remissions, compared with standard care (32% vs. 18%, odds ratio 2.17, 95% confidence interval 1.28 to 3.68; p = 0.004), and reduced fatigue [mean difference –18, 95% confidence interval –24 to –11 (scale 0–100); p < 0.001]. Disability (as measured on the Health Assessment Questionnaire) decreased when intensive management patients achieved remission (difference –0.40, 95% confidence interval –0.57 to –0.22) and these differences were considered clinically relevant. However, in all intensive management patients reductions in the Health Assessment Questionnaire scores were less marked (difference –0.1, 95% confidence interval –0.2 to 0.0). The numbers of serious adverse events (intensive management n = 15 vs. standard care n = 11) and other adverse events (intensive management n = 114 vs. standard care n = 151) were similar. Economic analysis showed that the base-case incremental cost-effectiveness ratio was £43,972 from NHS and Personal Social Services cost perspectives. The probability of meeting a willingness-to-pay threshold of £30,000 was 17%. The incremental cost-effectiveness ratio decreased to £29,363 after including patients’ personal costs and lost working time, corresponding to a 50% probability that intensive management is cost-effective at English willingness-to-pay thresholds. Analysing trial baseline predictors showed that remission predictors comprised baseline DAS28-ESR, disability scores and body mass index. A 6-month extension study (involving 95 intensive management patients) showed fewer remissions by 18 months, although more sustained remissions were more likley to persist. Qualitative research in trial completers showed that intensive management was acceptable and treatment support from specialist nurses was beneficial.
Limitations
The main limitations comprised (1) using single time point remissions rather than sustained responses, (2) uncertainty about benefits of different aspects of intensive management and differences in its delivery across centres, (3) doubts about optimal treatment of patients unresponsive to intensive management and (4) the lack of formal international definitions of ‘intensive management’.
Conclusion
The benefits of intensive management need to be set against its additional costs. These were relatively high. Not all patients benefited. Patients with high pretreatment physical disability or who were substantially overweight usually did not achieve remission.
Future work
Further research should (1) identify the most effective components of the intervention, (2) consider its most cost-effective delivery and (3) identify alternative strategies for patients not responding to intensive management.
Trial registration
Current Controlled Trials ISRCTN70160382.
Funding
This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research; Vol. 9, No. 8. See the NIHR Journals Library website for further project information.
Collapse
Affiliation(s)
- David L Scott
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Fowzia Ibrahim
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Harry Hill
- ScHARR Health Economics and Decision Science, The University of Sheffield, Sheffield, UK
| | - Brian Tom
- MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
| | - Louise Prothero
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Rhiannon R Baggott
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | | | - James B Galloway
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Sofia Georgopoulou
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Naomi Martin
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Isabel Neatrour
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Elena Nikiphorou
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Jackie Sturt
- Department of Adult Nursing, Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King’s College London, London, UK
| | - Allan Wailoo
- ScHARR Health Economics and Decision Science, The University of Sheffield, Sheffield, UK
| | - Frances MK Williams
- Twin Research and Genetic Epidemiology, School of Life Course Sciences, King’s College London, St Thomas’ Hospital, London, UK
| | - Ruth Williams
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| | - Heidi Lempp
- Centre for Rheumatic Diseases, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King’s College London, London, UK
| |
Collapse
|
8
|
Eberhard A, Bergman S, Mandl T, Olofsson T, Rydholm M, Jacobsson L, Turesson C. Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study. Arthritis Res Ther 2021; 23:169. [PMID: 34127054 PMCID: PMC8201925 DOI: 10.1186/s13075-021-02550-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 05/25/2021] [Indexed: 01/12/2023] Open
Abstract
Objectives Pain is a major symptom in patients with rheumatoid arthritis (RA). In early RA, pain is usually due to synovitis, but can also persist despite effective anti-inflammatory treatment. The objective of this study was to investigate the pain course over time and predictors of unacceptable pain and unacceptable pain with low inflammation, in patients with early RA. Methods An inception cohort of 232 patients with early RA, recruited in 1995–2005, was followed in a structured programme for 5 years. Pain was assessed using a visual analogue scale (VAS; 0–100). Unacceptable pain was defined as VAS pain > 40 based on the patient acceptable symptom state (PASS) and low inflammation as CRP < 10 mg/l. Baseline predictors of unacceptable pain were evaluated using logistic regression analysis. Results Pain improved significantly during the first 6 months, but then remained basically unchanged. Thirty-four per cent of the patients had unacceptable pain 5 years after inclusion. Baseline predictors of unacceptable pain after 5 years were lower swollen joint counts [odds ratio (OR) 0.71 per standard deviation (95% confidence interval (CI) 0.51–0.99)] and higher VAS for pain and global assessment of disease activity. Unacceptable pain with low inflammation after 5 years was negatively associated with anti-CCP antibodies [OR 0.50 (95% CI 0.22–0.98)]. Conclusion Over one third of the patients had unacceptable pain 5 years after inclusion. Lower swollen joint count was associated with unacceptable pain at 5 years. The results may be explained by the positive effects of treatment on pain related to inflammation. Non-inflammatory long-lasting pain appears to be a greater problem in anti-CCP-negative patients. Supplementary Information The online version contains supplementary material available at 10.1186/s13075-021-02550-7.
Collapse
Affiliation(s)
- Anna Eberhard
- Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 1b, 214 28, Malmö, Sweden.
| | - Stefan Bergman
- Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.,Department of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Thomas Mandl
- Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 1b, 214 28, Malmö, Sweden
| | - Tor Olofsson
- Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| | - Maria Rydholm
- Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 1b, 214 28, Malmö, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| | - Lennart Jacobsson
- Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg, Sweden
| | - Carl Turesson
- Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Jan Waldenströms gata 1b, 214 28, Malmö, Sweden.,Department of Rheumatology, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
9
|
Combe B, Rincheval N, Berenbaum F, Boumier P, Cantagrel A, Dieude P, Dougados M, Fautrel B, Flipo RM, Goupille P, Mariette X, Saraux A, Schaeverbeke T, Sibilia J, Vittecoq O, Daurès JP. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford) 2021; 60:5073-5079. [PMID: 33961011 DOI: 10.1093/rheumatology/keab398] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 04/27/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE To report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome. METHODS From 2003 to 2005, 813 patients were included if they had early arthritis (< 6 months) with a high probability of RA and had never been prescribed DMARDs. Multivariate analysis was used to evaluate predictors of outcome. RESULTS In total, 521 (64.1%) RA patients were followed up for 10 years; 35 (4.3%) died which appears similar to the French general population. Overall, 480 (92.1%) patients received a DMARD; 174 (33.4%) received at least one biologic DMARD, 13.6% within 2 years. At year 10, 273 (52.4%) patients were in DAS28 remission, 40.1% in sustained remission, 14.1% in drug-free remission, 39.7% in CDAI remission. Half of the patients achieved a HAQ-DI < 0.5. SF-36 physical component and pain were well controlled. Structural progression was weak, with a mean change from baseline in modified Sharp score of 11.0 ± 17.9. Only 34 (6.5%) patients required major joint surgery. A substantial number of patients showed new comorbidities over 10 years. Positivity for ACPA was confirmed as a robust predictor of long-term outcome. CONCLUSIONS We report a very mild 10-year outcome of a large cohort of patients with early RA diagnosed in the early 2000s, which was much better than results for a previous cohort of patients who were recruited in 1993. This current favourable outcome may be related to more intensive care for real-life patients.
Collapse
Affiliation(s)
- Bernard Combe
- CHU Montpellier, Montpellier University, Montpellier, France
| | - Nathalie Rincheval
- CHU Montpellier, Montpellier University, Montpellier, France.,Statistiques, University Institute of Clinical Research, Montpellier, France
| | - Francis Berenbaum
- Sorbonne Université, INSERM CRSA, AP-HP Saint Antoine hospital, Paris, France
| | | | | | - Philippe Dieude
- Université de Paris, AP-HP, Hôpital Bichat, DMU Locomotion, UMR 1152, INSERM, Paris, France
| | - Maxime Dougados
- Paris-Descartes University; UPRES-EA 4058; Cochin Hospital, Paris
| | - Bruno Fautrel
- Sorbonne Université APHP, Pierre Louis Institute of Epidemiology and Public Health INSERM UMRS 1136, Rheumatology Department, Pitié Salpêtrière University Hospital, Paris, France
| | - René-Marc Flipo
- Lille University Hospital, Lille 2 University, Lille, France
| | - Philippe Goupille
- Université de Tours, EA 7501; CHU de Tours, CIC INSERM 1415, Tours, France
| | - Xavier Mariette
- Université Paris-Saclay, AP-HP, Hôpital Bicêtre, INSERM UMR1184, Le Kremlin Bicêtre, France
| | | | | | - Jean Sibilia
- Strasbourg University Hospital, Strasbourg, France
| | - Olivier Vittecoq
- Rheumatology Department & CIC-CRB 1404, Rouen University Hospital, Inserm U1234, Rouen, Normandy, France
| | - Jean-Pierre Daurès
- Statistiques, University Institute of Clinical Research, Montpellier, France
| |
Collapse
|
10
|
Carpenter L, Nikiphorou E, Kiely PDW, Walsh DA, Young A, Norton S. Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. Rheumatology (Oxford) 2021; 59:2381-2391. [PMID: 31899521 PMCID: PMC7449804 DOI: 10.1093/rheumatology/kez635] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Revised: 11/22/2019] [Indexed: 11/21/2022] Open
Abstract
Objectives To examine secular trends in the progression of clinical and patient-reported outcomes in early RA. Methods A total of 2701 patients recruited to the Early Rheumatoid Arthritis Study or Early Rheumatoid Arthritis Network with year of diagnosis from 1986 to 2011. The 5-year progression rates for patients diagnosed at different points in time were modelled using mixed-effects regression; 1990, 2002 and 2010, were compared. Clinical markers of disease included the 28-joint count DAS and the ESR. Patient-reported markers included the HAQ, visual analogue scale of pain and global health, and the Short-Form 36. Results Statistically significant improvements in both 28-joint count DAS and ESR were seen over the 5 years in patients diagnosed with RA compared with those diagnosed earlier. By 5 years, 59% of patients with diagnosis in 2010 were estimated to reach low disease activity compared with 48% with diagnosis in 2002 and 32% with diagnosis in 1990. Whilst HAQ demonstrated statistically significant improvements, these improvements were small, with similar proportions of patients achieving HAQ scores of ≤1.0 by 5 years with a diagnosis in 1990 compared with 2010. Levels of the visual analogue scale and the Mental Component Scores of the Short-Form 36 indicated similar, statistically non-significant levels over the 5 years, irrespective of year diagnosed. Conclusion This study demonstrates improvements in inflammatory markers over time in early RA, in line with improved treatment strategies. These have not translated into similar improvements in patient-reported outcomes relating to either physical or mental health.
Collapse
Affiliation(s)
| | | | - Patrick D W Kiely
- Department of Rheumatology, St George's University Hospital NHS Foundation TrustLondon, UK.,Institute of Medical and Biomedical Education, St George's University of London, LondonUK
| | - David A Walsh
- Arthritis UK Pain Centre, University of Nottingham, Nottingham, UK
| | - Adam Young
- Postgraduate Medicine, University of Hertfordshire, Hatfield, UK
| | - Sam Norton
- Health Psychology Section, King's College LondonUK.,Centre for Rheumatic Diseases, King's College LondonUK
| |
Collapse
|
11
|
Lee YH, Ko PY, Kao SL, Lin MC, Cheng-Chung Wei J. Risk of Total Knee and Hip Arthroplasty in Patients With Rheumatoid Arthritis: A 12-Year Retrospective Cohort Study of 65,898 Patients. J Arthroplasty 2020; 35:3517-3523. [PMID: 32778419 DOI: 10.1016/j.arth.2020.06.085] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 06/22/2020] [Accepted: 06/29/2020] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Rheumatoid arthritis (RA) is an inflammatory disease that causes the destruction of soft tissues and cartilage around joints. Owing to the widespread use of potent disease-modifying antirheumatic drugs, the need for total knee and hip arthroplasties (TKA and THA) has been reduced in patients with RA. However, the current association between RA and either THA or TKA has not been demonstrated in large-scale epidemiological studies. METHODS We conducted a large-scale retrospective cohort study of patients diagnosed with RA during a 12-year period (2000-2012) in Taiwan. We recruited 32,949 patients with RA and 32,949 individually propensity score-matched non-RA controls. RESULTS After adjusting for confounding factors, we found that the risk of THA or TKA was 4.02 times higher in patients with RA than in those without RA (95% confidence interval [CI], 3.77-4.52). The risk of THA or TKA was highest in patients with RA younger than 40 years (adjusted hazard ratio, 43.18; 95% CI, 16.01-116.47). Compared with non-RA patients, patients with RA were 4.82 times more likely to undergo THA (95% CI, 3.84-6.04), 3.85 times more likely to undergo TKA (95% CI, 3.48-4.25), and 19.06 times more likely to undergo both THA and TKA (95% CI, 8.90-40.80). CONCLUSION These findings document a 4.02-fold greater long-term risk of undergoing THA or TKA in RA patients relative to non-RA patients in Taiwan.
Collapse
Affiliation(s)
- Yung-Heng Lee
- Department of Health Services Administration, China Medical University, Taichung, Taiwan; Department of Public Health, China Medical University, Taichung, Taiwan; Department of Orthopedics, Cishan Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan; Department of Center for General Education, National United University, Miaoli, Taiwan
| | - Po-Yun Ko
- Department of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan
| | - Su-Ling Kao
- Department of Human Resource, Chia Yi Hospital, Ministry of Health and Welfare, Chia Yi, Taiwan
| | - Mei-Chen Lin
- Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan
| | - James Cheng-Chung Wei
- Department of Rheumatology, BenQ Medical Center, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, China; Department of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
| |
Collapse
|
12
|
Paudyal S, Waller JL, Oliver A, Le B, Zleik N, Nahman NS, Carbone L. Rheumatoid Arthritis and Mortality in End Stage Renal Disease. J Clin Rheumatol 2020; 26:48-53. [PMID: 32073514 DOI: 10.1097/rhu.0000000000000916] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To determine whether rheumatoid arthritis (RA) is a risk factor for cardiovascular disease (CVD) events, all-cause mortality and cardiovascular mortality in End Stage Renal Disease (ESRD). METHODS Cohort study of adult patients with ESRD in the United States Renal Data System (USRDS) with RA and a 5% random sample of those without RA. CVD events, all-cause mortality and cardiovascular mortality were determined in those with RA compared to those without RA using Cox Proportional Hazards modeling. RESULTS 2,824 subjects, 407 with RA and 2,417 without RA, were included in the analyses. The duration of the study was up to 5 years, depending on mortality and initiation of dialysis. There were no significant differences in CVD events by RA status (n = 311 [76.4% RA] vs. n = 1936 [80.1% without RA], p = 0.09). Subjects with RA had a significantly shorter mean time in months from start of dialysis to an incident CVD event (20.1 ± 12.2 vs. 21.2 ± 14.1, p < 0.01) than those without RA. In multivariable adjusted models, RA was not associated with an increased risk for all-cause mortality (aHR = 1.09, 95%CI 0.94-1.27) or cardiovascular mortality (aHR = 0.95, 95% CI 0.74-1.22) within 5 years. Risk factors for all-cause mortality and cardiovascular mortality in RA included older age and a higher Charlson comorbidity index (CCI). CONCLUSIONS Clinicians should be aware that persons with RA who develop ESRD incur cardiac events sooner than the general population. However, RA is not an independent risk factor for all-cause or cardiovascular mortality in ESRD.
Collapse
Affiliation(s)
- Sunita Paudyal
- From the Division of Rheumatology, University of South Carolina School of Medicine, Columbia, SC
| | - Jennifer L Waller
- Department of Population Health Sciences, Division of Biostatistics and Data Science, Medical College of Georgia at Augusta University, Augusta, GA
| | - Alyce Oliver
- Department of Medicine, Division of Rheumatology and Adult Allergy, Medical College of Georgia at Augusta University, Augusta, GA
| | - Brian Le
- Department of Medicine, Division of Rheumatology and Adult Allergy, Medical College of Georgia at Augusta University, Augusta, GA
- Charlie Norwood Veterans Affairs Medical Center, Augusta, GA
| | - Nour Zleik
- Department of Medicine, Division of Rheumatology and Adult Allergy, Medical College of Georgia at Augusta University, Augusta, GA
- Charlie Norwood Veterans Affairs Medical Center, Augusta, GA
| | - N Stanley Nahman
- Department of Medicine, Division of Nephrology, Medical College of Georgia at Augusta University, Augusta, GA
- Charlie Norwood Veterans Affairs Medical Center, Augusta, GA
| | - Laura Carbone
- Charlie Norwood Veterans Affairs Medical Center, Augusta, GA
- Department of Medicine, Medical College of Georgia, Augusta University, Augusta GA
| |
Collapse
|
13
|
|
14
|
Einarsson JT, Willim M, Saxne T, Geborek P, Kapetanovic MC. Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden. Rheumatology (Oxford) 2019; 59:205-212. [DOI: 10.1093/rheumatology/kez273] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2019] [Revised: 06/03/2019] [Indexed: 11/14/2022] Open
Abstract
Abstract
Objectives
The aim of this study of patients with RA in Sweden was to investigate secular trends in achieving sustained remission (SR), i.e. DAS28 <2.6 on at least two consecutive occasions and lasting for at least 6 months.
Methods
All adult RA patients registered in the Swedish Rheumatology Quality register through 2012, with at least three registered visits were eligible, a total of 29 084 patients. Year of symptom onset ranged from 1955, but for parts of the analysis only patients with symptom onset between 1994 and 2009 were studied. In total, 95% of patients fulfilled the ACR 1987 classification criteria for RA. Odds of reaching SR for each decade compared with the one before were calculated with logistic regression and individual years of symptom onset were compared with life table analysis.
Results
Of patients with symptom onset in the 1980s, 1990s and 2000s, 35.0, 43.0 and 45.6% reached SR, respectively (P < 0.001 for each increment), and the odds of SR were higher in every decade compared with the one before. The hazard ratio for reaching SR was 1.15 (95% CI 1.14, 1.15) for each year from 1994 to 2009 compared with the year before. Five years after symptom onset in 2009, 45.3% of patients had reached SR compared with 15.9% in 1999.
Conclusion
There is a clear secular trend towards increased incidence of SR in patients with RA in Sweden. This trend most likely reflects earlier diagnosis and treatment start, and adherence to national and international guidelines recommending the treat to target approach.
Collapse
Affiliation(s)
- Jon T Einarsson
- Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
| | - Minna Willim
- Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
| | - Tore Saxne
- Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
| | - Pierre Geborek
- Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
| | - Meliha C Kapetanovic
- Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden
| |
Collapse
|
15
|
Johnson BK, Bahçe-Altuntaş A. Too Little Too Late: Effect of Poor Access to Biologics for Patients with Rheumatoid Arthritis. J Rheumatol 2019; 44:1765-1766. [PMID: 29196544 DOI: 10.3899/jrheum.171148] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Beverly K Johnson
- Assistant Professor of Medicine, Albert Einstein College of Medicine, Director of Rheumatology, Jacobi Medical Center and North Central Bronx (NCB) Hospital;
| | - Asena Bahçe-Altuntaş
- Assistant Professor of Medicine, Albert Einstein College of Medicine, Director of the Joint Pain Clinic, Jacobi/NCB, New York, New York, USA
| |
Collapse
|
16
|
Gullick NJ, Ibrahim F, Scott IC, Vincent A, Cope AP, Garrood T, Panayi GS, Scott DL, Kirkham BW. Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis. BMC Rheumatol 2019; 3:6. [PMID: 30886994 PMCID: PMC6390620 DOI: 10.1186/s41927-019-0054-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Accepted: 01/25/2019] [Indexed: 12/25/2022] Open
Abstract
Background The emphasis on treating rheumatoid arthritis (RA) intensively reduces disease activity but its impact in routine care is uncertain. We evaluated temporal changes in disease activities and outcomes in a 10-year prospective observational cohort study of patients in routine care at one unit. Methods The Guy’s and St Thomas’ RA cohort was established in 2005. It involved most RA patients managed in this hospital. Clinical diagnoses of RA were made by rheumatologists. Patients were seen regularly in routine care. Each visit included measurement of disease activity scores for 28 joints (DAS28), health assessment questionnaire scores (HAQ) and EuroQol scores. Patients received intensive treatments targeting DAS28 remission. Results In 1693 RA patients mean DAS28 scores fell from 2005 to 15 by 11% from 4.08 (95% CI: 3.91, 4.25) in 2005 to 3.64 (3.34, 3.78); these falls were highly significant (p < 0.001). DAS28 components: swollen joint counts fell by 32% and ESR by 24%; in contrast tender joint counts and patient global assessments showed minimal or no reductions. The reduction in DAS28 scores was predominantly between 2005 and 2010, with no falls from 2011 onwards. Associated with falls in mean DAS28s, patients achieving remission increased (18% in 2005; 27% in 2015) and the number with active disease (DAS28 > 5.1) decreased (25% in 2005; 16% in 2015). In 752 patients seen at least annually for 3 years, persisting remission (68 patients) and intermittent remission (376 patients) were associated with less disability and better health related quality of life. Over time biologic use increased, but they were used infrequently in patients in persistent remission. Conclusions Over 10 years an intensive management strategy in a routine practice setting increased combination DMARD and biologic use: disease activity levels declined; this association is in keeping with a causal relationship. Patients who achieved remission, even transiently, had better functional outcomes than patients never achieving remission. Electronic supplementary material The online version of this article (10.1186/s41927-019-0054-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Nicola J Gullick
- 1Department of Rheumatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
| | - Fowzia Ibrahim
- 2Department of Rheumatology, 3rd Floor, Weston Education Centre, King's College London, Cutcombe Road, London, UK
| | - Ian C Scott
- 3Research Institute for Primary Care & Health Sciences, Primary Care Sciences, Keele University, Keele, Staffordshire UK.,4Department of Rheumatology, Haywood Hospital, High Lane, Burslem, Staffordshire UK.,6Academic Department of Rheumatology, Centre for Molecular and Cellular Biology of Inflammation, 1st Floor, New Hunt's House, Guy's Campus, King's College London, Great Maze Pond, London, UK
| | - Alexandra Vincent
- 5Department of Rheumatology, Guy's and St Thomas' NHS Trust, 4th Floor, Tower Wing, Guy's Hospital, Great Maze Pond, London, UK
| | - Andrew P Cope
- 5Department of Rheumatology, Guy's and St Thomas' NHS Trust, 4th Floor, Tower Wing, Guy's Hospital, Great Maze Pond, London, UK.,6Academic Department of Rheumatology, Centre for Molecular and Cellular Biology of Inflammation, 1st Floor, New Hunt's House, Guy's Campus, King's College London, Great Maze Pond, London, UK
| | - Toby Garrood
- 5Department of Rheumatology, Guy's and St Thomas' NHS Trust, 4th Floor, Tower Wing, Guy's Hospital, Great Maze Pond, London, UK
| | - Gabriel S Panayi
- 5Department of Rheumatology, Guy's and St Thomas' NHS Trust, 4th Floor, Tower Wing, Guy's Hospital, Great Maze Pond, London, UK
| | - David L Scott
- 2Department of Rheumatology, 3rd Floor, Weston Education Centre, King's College London, Cutcombe Road, London, UK
| | - Bruce W Kirkham
- 5Department of Rheumatology, Guy's and St Thomas' NHS Trust, 4th Floor, Tower Wing, Guy's Hospital, Great Maze Pond, London, UK
| | | |
Collapse
|
17
|
Petersson S, Philippou E, Rodomar C, Nikiphorou E. The Mediterranean diet, fish oil supplements and Rheumatoid arthritis outcomes: evidence from clinical trials. Autoimmun Rev 2018; 17:1105-1114. [PMID: 30213690 DOI: 10.1016/j.autrev.2018.06.007] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2018] [Accepted: 06/08/2018] [Indexed: 02/08/2023]
Abstract
The impact of dietary interventions such as specific types of diet or nutritional supplements in rheumatoid arthritis (RA) has been subject to increased attention in recent years. The recognition of the unmet need to better understand the effects of specific dietary interventions on disease outcomes in RA, along with the growing patient interest on lifestyle interventions beyond pharmacotherapy, have informed the undertaking of this narrative literature review. The benefits of the Mediterranean Diet (MD) have been shown in various studies, although only a limited number of trials focus specifically on RA. Based on the studies reviewed, the MD may provide benefits in reducing pain and swollen and tender joints in RA patients. There is more and better evidence that n-3 polyunsaturated fat (PUFA) supplementation has the potential to reduce inflammation and provide clinical benefit, possibly slowing progression to pharmacotherapy. Yet, many of these studies to date are limited in their methodology; this being partly a reflection of the complexity of the research questions being addressed. Consequently, the conclusions that can be robustly drawn from their results are restricted. With a focus on clinical trials on the MD and fish oil supplementation, this review critically appraises the evidence, discussing the findings of studies in the wider context of impact on RA outcomes, methodological challenges, and practical points to consider as part of the routine care of RA patients.
Collapse
Affiliation(s)
- Sara Petersson
- Department of Life and Health Sciences, University of Nicosia, Cyprus
| | - Elena Philippou
- Department of Life and Health Sciences, University of Nicosia, Cyprus; Diabetes and Nutritional Sciences Division, King's College London, London, UK.
| | - Carrie Rodomar
- University of Nicosia Medical School, University of Nicosia, Cyprus
| | - Elena Nikiphorou
- Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| |
Collapse
|
18
|
Boer AC, Boonen A, van der Helm van Mil AHM. Is Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti-Citrullinated Protein Antibody-Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward. Arthritis Care Res (Hoboken) 2018; 70:987-996. [PMID: 29266813 PMCID: PMC6033104 DOI: 10.1002/acr.23497] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 12/12/2017] [Indexed: 11/19/2022]
Abstract
Objective Because of its association with joint destruction, anti–citrullinated protein antibody (ACPA)–positive rheumatoid arthritis (RA) is considered to be more severe than ACPA‐negative RA. Clinically relevant joint destruction is now infrequent thanks to adequate disease suppression. According to patients, important outcomes are pain, fatigue, and independence. We evaluated whether ACPA‐positive RA patients diagnosed during or after 2000 have more severe self‐reported limitations and impairments, including restrictions at work, than ACPA‐negative RA patients. Methods A total of 492 ACPA‐positive and 450 ACPA‐negative RA patients who fulfilled the 2010 criteria and were included in the Leiden Early Arthritis Clinic cohort during or after 2000 were compared for self‐reported pain, fatigue, disease activity, general well‐being (measured by numerical rating scales), physical function (measured by the Health Assessment Questionnaire), and work restrictions, including absenteeism at baseline and during the 4‐year followup. Linear mixed models were used. Results At disease presentation, ACPA‐negative patients had more severe pain, fatigue, self‐reported disease activity scores, and functional disability (P < 0.05), although absolute differences were small. During followup, ACPA‐negative patients remained somewhat more fatigued (P = 0.002), whereas other patient‐reported impairments and limitations were similar. Thirty‐eight percent of ACPA‐negative and 48% of ACPA‐positive patients reported absenteeism (P = 0.30), with median 4 days missed in both groups in the last 3 months. Also, restrictions at work among employed patients and restrictions with household work were not statistically different at baseline and during followup. Conclusion In current rheumatology practice, ACPA‐positive RA is not more severe than ACPA‐negative RA in terms of patients’ relevant outcomes, including physical functioning and restrictions at work. This implies that efforts to further improve the disease course should be proportional to both disease subsets.
Collapse
Affiliation(s)
- Aleid C. Boer
- Leiden University Medical CenterLeidenThe Netherlands
| | - Annelies Boonen
- Care and Public Health Research Institute, and Maastricht University Medical CenterMaastrichtThe Netherlands
| | | |
Collapse
|
19
|
Taylor PC, Alten R, Gomez-Reino JJ, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. RMD Open 2018; 4:e000615. [PMID: 29593881 PMCID: PMC5869220 DOI: 10.1136/rmdopen-2017-000615] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Revised: 01/26/2018] [Accepted: 02/26/2018] [Indexed: 12/14/2022] Open
Abstract
Background Despite the wide array of treatments available for rheumatoid arthritis (RA), some patients continue to report unmet clinical needs. We investigated the extent of inadequate disease control in patients with RA. Methods Data were drawn from the Adelphi 2014 RA Disease-Specific Program in France, Germany, Italy, Spain and the UK. Rheumatologists provided patient demographics, comorbidities, satisfaction with RA control and other clinical details. Patients reported their level of satisfaction and completed the EuroQoL 5-Dimensions Health Questionnaire and Work Productivity and Activity Impairment Questionnaire. Patients had been on their current therapy ≥3 months and had 28-joint disease activity scores (DAS28) reported. Adequately controlled (DAS28 ≤3.2) and inadequately controlled (DAS28 >3.2) patient cohorts were compared using univariate tests. Results Of 1147 patients, 74% were women, the mean age was 52 years and the mean time since RA diagnosis was 7 years. Twenty-seven percent of patients had inadequately controlled RA, whereas 73% had adequately controlled RA. Inadequately controlled patients were more affected clinically versus adequately controlled patients; 69% vs 13% had moderate/severe RA, the current level of pain was 4.6 vs 2.3, and 67% vs 41% experienced flares, respectively (all p<0.0001). Inadequately controlled patients had higher rates of depression (16% vs 5%; p<0.0001), worse health state, greater work and activity impairment, and lower satisfaction rates among the patients and their physicians than the adequately controlled cohort. Conclusion RA was insufficiently controlled in over a quarter of patients despite their current therapy and this had a negative impact on the patients.
Collapse
Affiliation(s)
- Peter C Taylor
- Botnar Research Centre, University of Oxford, Oxford, UK
| | - Rieke Alten
- Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany
| | - Juan J Gomez-Reino
- Fundacion Ramon Dominguez and Rheumatology Unit, Hospital Clinico Universitario, Santiago, Spain
| | - Roberto Caporali
- IRCCS Foundation Policlinico S. Matteo, University of Pavia, Pavia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Goodman SM, Bykerk VP, DiCarlo E, Cummings RW, Donlin LT, Orange DE, Hoang A, Mirza S, McNamara M, Andersen K, Bartlett SJ, Szymonifka J, Figgie MP. Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors. J Rheumatol 2018; 45:604-611. [PMID: 29545451 DOI: 10.3899/jrheum.170366] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/29/2017] [Indexed: 12/30/2022]
Abstract
OBJECTIVE Rates of total knee arthroplasty (TKA) and total hip arthroplasty (THA) remain high for patients with rheumatoid arthritis (RA), who are at risk of flaring after surgery. We aimed to describe rates, characteristics, and risk factors of RA flare within 6 weeks of THA and TKA. METHODS Patients with RA were recruited prior to elective THA and TKA surgery and prospectively followed. Clinicians evaluated RA clinical characteristics 0-2 weeks before and 6 weeks after surgery. Patients answered questions regarding disease activity including self-reported joint counts and flare status weekly for 6 weeks. Per standard of care, biologics were stopped before surgery, while glucocorticoids and methotrexate (MTX) were typically continued. Multivariable logistic regression was used to identify baseline characteristics associated with postsurgical RA flares. RESULTS Of 120 patients, the mean age was 62 years and the median RA duration 14.8 years. Ninety-eight (82%) met 2010/1987 American College of Rheumatology/European League Against Rheumatism criteria, 53 (44%) underwent THA (and the rest TKA), and 61 (51%) were taking biologics. By 6 weeks, 75 (63%) had flared. At baseline, flarers had significantly higher disease activity (as measured by the 28-joint Disease Activity Score), erythrocyte sedimentation rate, C-reactive protein, and pain. Numerically more flarers used biologics, but stopping biologics did not predict flares, and continuing MTX was not protective. A higher baseline disease activity predicted flaring by 6 weeks (OR 2.12, p = 0.02). CONCLUSION Flares are frequent in patients with RA undergoing arthroplasty. Higher baseline disease activity significantly increases the risk. Although more patients stopping biologics flared, this did not independently predict flaring. The effect of early postsurgery flares requires further study.
Collapse
Affiliation(s)
- Susan M Goodman
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. .,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery.
| | - Vivian P Bykerk
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Edward DiCarlo
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Ryan W Cummings
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Laura T Donlin
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Dana E Orange
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Annie Hoang
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Serene Mirza
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Michael McNamara
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Kayte Andersen
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Susan J Bartlett
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Jackie Szymonifka
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| | - Mark P Figgie
- From the Departments of Rheumatology and Orthopedics, Hospital for Special Surgery; Rockefeller University, New York, New York, USA; Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity, Toronto, Ontario; the departments of Clinical Epidemiology and Rheumatology, McGill University, Montreal, Quebec, Canada; the Department of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.,S.M. Goodman, MD, Department of Rheumatology, Hospital for Special Surgery; V.P. Bykerk, MD, Department of Rheumatology, Hospital for Special Surgery, and Mount Sinai Hospital, Rebecca McDonald Center for Arthritis and Autoimmunity; E. DiCarlo, MD, Hospital for Special Surgery; R.W. Cummings, BA, Hospital for Special Surgery; L.T. Donlin, PhD, Hospital for Special Surgery; D.E. Orange, MD, Rockefeller University; A. Hoang, MD, Hospital for Special Surgery; S. Mirza, BA, Hospital for Special Surgery; M. McNamara, BA, Hospital for Special Surgery; K. Andersen, BA, Hospital for Special Surgery; S.J. Bartlett, PhD, departments of Clinical Epidemiology and Rheumatology, McGill University, and Department of Rheumatology, Johns Hopkins School of Medicine; J. Szymonifka, PhD, Department of Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Department of Orthopedics, Hospital for Special Surgery
| |
Collapse
|
21
|
Annapureddy N, Giangreco D, Devilliers H, Block JA, Jolly M. Psychometric properties of MDHAQ/RAPID3 in patients with systemic lupus erythematosus. Lupus 2018; 27:982-990. [DOI: 10.1177/0961203318758503] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- N Annapureddy
- Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA
| | - D Giangreco
- Division of Rheumatology, Department of Medicine, Rush University Medical Center, Chicago, IL, USA
| | - H Devilliers
- Internal Medicine and Systemic Disease Unit, Dijon University Hospital, Dijon, France
| | - J A Block
- Division of Rheumatology, Department of Medicine, Rush University Medical Center, Chicago, IL, USA
| | - M Jolly
- Division of Rheumatology, Department of Medicine, Rush University Medical Center, Chicago, IL, USA
| |
Collapse
|
22
|
Goodman SM. Do Recent Trends in RA Surgery Reflect Success in Disease Management? J Rheumatol 2018; 45:147-149. [PMID: 29419445 DOI: 10.3899/jrheum.171056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Susan M Goodman
- Attending Rheumatologist, Division of Rheumatology, Hospital for Special Surgery, Professor of Clinical Medicine, Department of Medicine, Weill Cornell Medical School, New York, New York, USA.
| |
Collapse
|
23
|
Smolen JS, Szumski A, Koenig AS, Jones TV, Marshall L. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial. Arthritis Res Ther 2018; 20:8. [PMID: 29338762 PMCID: PMC5771183 DOI: 10.1186/s13075-017-1484-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Accepted: 11/22/2017] [Indexed: 12/22/2022] Open
Abstract
Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanercept or etanercept withdrawal. Methods Patients with Disease Activity Score based on 28-joint count (DAS28) >3.2 and ≤5.1 received open-label etanercept 50 mg once weekly (QW) plus methotrexate for 36 weeks. Those who achieved DAS28 low disease activity by 36 weeks were randomized to double-blind treatment with etanercept 50 mg or 25 mg QW plus methotrexate or placebo plus methotrexate for 52 weeks. All analyses were adjusted for the continuous baseline variables of their respective remission outcomes. Results Younger age, body mass index (BMI) <30 kg/m2, and lower Health Assessment Questionnaire (HAQ) score at baseline were significant predictors of week-36 remission (P < 0.05) based on DAS28, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI). Baseline DAS28, SDAI, and CDAI were significantly predictive of all three remission endpoints (P < 0.05). For all three treatments, the strongest predictors of loss of DAS28 remission included failure to achieve sustained remission (DAS28 < 2.6 at weeks 12, 20, 28, and 36) with induction therapy, higher DAS28/SDAI/CDAI at randomization and at 1 month, increase in DAS28/SDAI/CDAI at 1 month, and increase in DAS28/CDAI/SDAI components and patient-reported outcomes (PROs) at 1 month. With the exception of not achieving sustained remission, very similar significant predictors were observed for loss of SDAI and CDAI remission. Conclusion These findings suggest that patients with moderately active RA who are younger and have lower BMI, lower HAQ, and lower disease activity at baseline are most likely to achieve remission when receiving combination etanercept and methotrexate induction therapy. In addition, patients who fail to achieve sustained remission with induction therapy and those with worse disease activity and PROs at early time points after initiating maintenance therapy with a full-dose or reduced-dose etanercept-methotrexate regimen or methotrexate monotherapy are most likely to lose remission across all treatment arms. These findings may help guide clinicians’ decision-making as they treat patients to remission and beyond. Trial registration ClinicalTrials.gov, NCT00565409. Registered on 28 November 2007 Electronic supplementary material The online version of this article (10.1186/s13075-017-1484-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Josef S Smolen
- Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. .,Hietzing Hospital, Vienna, Austria.
| | | | | | | | | |
Collapse
|
24
|
Raheel S, Matteson EL, Crowson CS, Myasoedova E. Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study. Rheumatology (Oxford) 2017; 56:2154-2161. [PMID: 28968703 DOI: 10.1093/rheumatology/kex352] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Indexed: 12/24/2022] Open
Abstract
Objective To assess trends in the occurrence of flares and remission in RA over recent decades. Methods A retrospective medical records review of each clinical visit was performed in a population-based cohort of patients with RA (age ⩾30 years; 1987 ACR criteria met in 1988-2007) to estimate flare and remission status. RA flare was defined as any worsening of RA activity leading to an initiation, change or increase of therapy (OMERACT 9). The primary definition for remission required the absence of RA disease activity (i.e. tender joint count 0, swollen joint count 0 and ESR ⩽10 mm/h) (OMERACT 7). All subjects were followed until death, migration or 1 July 2012. Results The study included 650 RA patients (mean age 55.8 years; 69% female) with a mean follow up of 10.3 years. Patients were flaring at 2887 (17%) visits. There was a significant decline in the RA flare rate across disease duration (P < 0.001), predominantly in the first 5 years after diagnosis of RA. Patients diagnosed with RA in more recent years experienced fewer flares during first few years of RA (P < 0.001). There was no difference between the sexes in trends of flare rates over time (P = 0.42) Current smokers had higher flare rates than non-smokers (P = 0.047) and former smokers were not different from non-smokers (P = 0.87). Conclusion Patients diagnosed in more recent years have lower flare rates than those diagnosed in prior decades. Flare rates declined fastest in the first 5 years of disease and tended to be stable thereafter. Current smoking was associated with an adverse flare profile.
Collapse
Affiliation(s)
- Shafay Raheel
- Division of Rheumatology, Department of Internal Medicine
| | - Eric L Matteson
- Division of Rheumatology, Department of Internal Medicine.,Division of Epidemiology, Department of Health Sciences Research
| | - Cynthia S Crowson
- Division of Rheumatology, Department of Internal Medicine.,Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
| | | |
Collapse
|
25
|
Carpenter L, Norton S, Nikiphorou E, Jayakumar K, McWilliams DF, Rennie KL, Dixey J, Kiely P, Walsh DA, Young A. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. Arthritis Care Res (Hoboken) 2017; 69:1809-1817. [DOI: 10.1002/acr.23217] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Accepted: 02/07/2017] [Indexed: 11/09/2022]
Affiliation(s)
- Lewis Carpenter
- Centre for Clinical and Health Service Research; University of Hertfordshire; Hatfield UK
| | - Sam Norton
- Institute of Psychiatry, Psychology and Neuroscience; University of Hertfordshire; Hatfield UK
| | | | | | | | - Kirsten L. Rennie
- Centre for Clinical and Health Service Research; University of Hertfordshire; Hatfield UK
| | | | - Patrick Kiely
- St Georges University Hospitals NHS Foundation Trust; London UK
| | | | - Adam Young
- University of Hertfordshire; Hatfield UK
| | | |
Collapse
|
26
|
Kawata M, Sasabuchi Y, Inui H, Taketomi S, Matsui H, Fushimi K, Chikuda H, Yasunaga H, Tanaka S. Annual trends in knee arthroplasty and tibial osteotomy: Analysis of a national database in Japan. Knee 2017; 24:1198-1205. [PMID: 28797877 DOI: 10.1016/j.knee.2017.06.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 04/29/2017] [Accepted: 06/08/2017] [Indexed: 02/02/2023]
Abstract
BACKGROUND Various nationwide studies have reported differing annual trends in utilization of knee arthroplasty and tibial osteotomy. Using the Diagnosis Procedure Combination database in Japan, the present series examined annual trends and demographics in total knee arthroplasty (TKA), unicompartmental knee arthroplasty (UKA) and tibial osteotomy. METHODS All patients were identified who underwent TKA, UKA or tibial osteotomy for osteoarthritis, osteonecrosis or rheumatoid arthritis of the knee between July 2007 and March 2015. RESULTS A total of 170,433 cases of TKA, 13,209 cases of UKA and 8760 cases of tibial osteotomy were identified. The proportion of patients undergoing UKA rose from 4.0% in 2007 to 8.1% in 2014 (P<0.001), and that of tibial osteotomy from 2.6% in 2007 to 5.5% in 2014 (P<0.001); the proportion undergoing TKA fell from 93.4% in 2007 to 86.3% in 2014 (P<0.001). Between 2007 and 2014 the proportions of patients with osteonecrosis who underwent UKA and tibial osteotomy increased from 34.7% and 11.6% to 38.6% and 16.2%, respectively (P=0.001 for UKA and P=0.004 for tibial osteotomy). The proportions of patients with osteonecrosis undergoing UKA or tibial osteotomy were significantly greater than those with other diagnoses (P<0.001 for both). CONCLUSIONS The popularity of UKA and tibial osteotomy in Japan increased during the period 2007-2014 at the expense of TKA. The proportions of UKA and tibial osteotomy in patients with osteonecrosis also increased, and were larger than those in patients with other causative diseases.
Collapse
Affiliation(s)
- Manabu Kawata
- Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
| | - Yusuke Sasabuchi
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hiroshi Inui
- Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
| | - Shuji Taketomi
- Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hiroki Matsui
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
| | - Kiyohide Fushimi
- Department of Health Informatics and Policy, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Hirotaka Chikuda
- Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Gunma, Japan
| | - Hideo Yasunaga
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
| | - Sakae Tanaka
- Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
27
|
Matsumoto T, Nishino J, Izawa N, Naito M, Hirose J, Tanaka S, Yasui T, Saisho K, Tohma S. Trends in Treatment, Outcomes, and Incidence of Orthopedic Surgery in Patients with Rheumatoid Arthritis: An Observational Cohort Study Using the Japanese National Database of Rheumatic Diseases. J Rheumatol 2017; 44:1575-1582. [PMID: 28864641 DOI: 10.3899/jrheum.170046] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2017] [Indexed: 01/28/2023]
Abstract
OBJECTIVE In this study, we investigated the changes in clinical outcome, treatment, and incidence of orthopedic surgery in patients with rheumatoid arthritis (RA) from 2004 to 2014. METHODS Data were studied from the Japanese nationwide cohort database, NinJa (National Database of Rheumatic Diseases by iR-net in Japan), from 2004 to 2014. The time trends in the incidence of orthopedic procedures were analyzed using linear regression analysis. The cross-sectional annual data were compared between 2004 and 2014 to analyze the changes in clinical outcome and treatment. RESULTS The incidence of orthopedic surgeries in patients with RA consistently decreased from 72.2 procedures per 1000 patients in 2004 to 51.5 procedures per 1000 patients in 2014 (regression coefficient = -0.0028, 95% CI -0.0038 to -0.0019, p < 0.001). The greatest reduction was found in total knee arthroplasty and total hip arthroplasty. Disease activity and functional disability improved significantly over this decade. The proportions of patients receiving methotrexate and biologic disease-modifying antirheumatic drugs significantly increased from 39.6% and 1.7% in 2004 to 63.8% and 27.4% in 2014, respectively. CONCLUSION The overall incidence of orthopedic surgeries in patients with RA significantly decreased, accompanied by improved clinical outcomes because of the expanded use of effective drugs; however, the declining trend differed between procedures or locations. The results from the present study suggest that there might be a change in supply and demand for orthopedic surgeries.
Collapse
Affiliation(s)
- Takumi Matsumoto
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan. .,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization.
| | - Jinju Nishino
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Naohiro Izawa
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Masashi Naito
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Jun Hirose
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Sakae Tanaka
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Testuro Yasui
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Koichiro Saisho
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| | - Shigeto Tohma
- From the Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo; Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization, Miyazaki; Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan.,T. Matsumoto, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Nishino, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; N. Izawa, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; M. Naito, MD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; J. Hirose, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; S. Tanaka, MD, PhD, Department of Orthopedic Surgery, Faculty of Medicine, The University of Tokyo; T. Yasui, MD, PhD, Department of Orthopedic Surgery, Teikyo University Mizonokuchi Hospital; K. Saisho, MD, PhD, Department of Rheumatology, Miyakonojo Medical Center, National Hospital Organization; S. Tohma, MD, PhD, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization
| |
Collapse
|
28
|
El-Haddad C, Castrejon I, Gibson KA, Yazici Y, Bergman MJ, Pincus T. MDHAQ/RAPID3 scores in patients with osteoarthritis are similar to or higher than in patients with rheumatoid arthritis: a cross-sectional study from current routine rheumatology care at four sites. RMD Open 2017; 3:e000391. [PMID: 29225915 PMCID: PMC5708309 DOI: 10.1136/rmdopen-2016-000391] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2016] [Revised: 04/17/2017] [Accepted: 05/12/2017] [Indexed: 11/25/2022] Open
Abstract
Objective To compare patients with a primary diagnosis of osteoarthritis (OA) versus rheumatoid arthritis (RA) for scores on a patient self-report MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data 3), and for physician global assessment (DOCGL). Methods All patients with all diagnoses complete an MDHAQ/RAPID3 at all routine rheumatology visits in the waiting area before seeing a rheumatologist at four sites, one in Australia and three in the USA. The two-page MDHAQ includes 0–10 scores for physical function (in 10 activities), pain and patient global assessment [on 0–10 visual analogue scales (VAS)], compiled into a 0–30 RAPID3, as well as fatigue and self-report painful joint count scales. Rheumatologists estimate a 0–10 DOCGL VAS. Demographic, MDHAQ/RAPID3 and DOCGL data from a random visit were compared in patients with RA versus patients with OA using multivariate analysis of variance, adjusted for age, disease duration and formal education level. Results Median RAPID3 was higher in OA versus RA at all four sites (11.7–16.8 vs 6.2–11.8) (p<0.001 at three sites). Median DOCGL in OA versus RA was 5 vs 4, 4 vs 3.7, 2.2 vs 2.5 and 2 vs 1. Patterns were similar for individual RAPID3 items, fatigue and painful joint scales, and in stratified analyses of patients aged 55–70. Conclusion Patient MDHAQ/RAPID3 and physician DOCGL indicate similar or higher disease burden in OA versus RA. Routine MDHAQ/RAPID3 allows direct comparisons of the two diseases. The findings suggest possible revision of current clinical and public policy views concerning OA.
Collapse
Affiliation(s)
- Carlos El-Haddad
- Department of Rheumatology, Liverpool Hospital, Liverpool, Australia
| | - Isabel Castrejon
- Division of Rheumatology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
| | - Kathryn A Gibson
- Department of Rheumatology, Liverpool Hospital, Liverpool, Australia.,Ingham Research Institute, Liverpool, Australia.,Rheumatology, University of New South Wales, Sydney, NSW, Australia
| | - Yusuf Yazici
- NYU Hospital for Joint Diseases, New York University School of Medicine, New York, New York, USA
| | - Martin J Bergman
- Department of Arthritis and Rheumatology, Taylor Hospital, Ridley Park, Pennsylvania, USA
| | - Theodore Pincus
- Division of Rheumatology, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA
| |
Collapse
|
29
|
Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2016; 83:625-630. [DOI: 10.1016/j.jbspin.2016.07.007] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2016] [Indexed: 01/15/2023]
|
30
|
Nikiphorou E, Norton S, Carpenter L, Dixey J, Andrew Walsh D, Kiely P, Young A. Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States. Arthritis Care Res (Hoboken) 2016; 69:21-27. [PMID: 27564223 DOI: 10.1002/acr.23014] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 07/08/2016] [Accepted: 08/09/2016] [Indexed: 12/31/2022]
Abstract
OBJECTIVE To examine secular trends in demographics, clinical manifestations, and comorbidity on first presentation of rheumatoid arthritis (RA) prior to disease-modifying antirheumatic drug treatment. METHODS A total of 2,701 patients were recruited over 25 years to 2 UK-based RA inception cohorts: the Early Rheumatoid Arthritis Study (9 centers; 1986-2001) and the Early Rheumatoid Arthritis Network (23 centers; 2002-2012). Trends in demographic and baseline clinical/laboratory and radiographic variables and comorbidities were estimated using mixed-effects models, including random effects for recruitment center. RESULTS Age at onset increased from 53.2 to 57.7 years in 1990 and 2010, respectively (2.6 months/year; 95% confidence interval [95% CI] 1.2, 4.1). Sex ratio, the proportion living in deprived areas, and smoking status were unchanged (P > 0.05) and there were no changes in the proportion seropositive or erosive at baseline (P > 0.05). After controlling for treatment at the time of assessment, erythrocyte sedimentation rate decreased and hemoglobin increased over time (P > 0.05); however, the Health Assessment Questionnaire (HAQ), the Disease Activity Score (DAS), the DAS in 28 joints, and joint counts were unchanged (P > 0.05). The overall prevalence of comorbidity increased from 29.0% in 1990 to 50.7% in 2010, mainly due to cardiovascular and non-cardiac vascular conditions, including hypertension. There was a significant increase in body mass index (0.15 units/year; 95% CI 0.11, 0.18), resulting in an increase in the prevalence of obesity from 13.3% in 1990 to 33.6% in 2010. CONCLUSION Age at onset and comorbidity burden, especially obesity, have increased at RA presentation over 25 years, reflecting wider demographic trends at the population level. In contrast, there were no accompanying changes in disease severity assessed by composite markers of disease activity, radiographic erosions, seropositivity, or HAQ at presentation. Treatment strategies in early RA should take greater account of the impact of comorbidity on outcomes.
Collapse
Affiliation(s)
- Elena Nikiphorou
- Whittington Hospital NHS Trust, London, UK, and Early Rheumatoid Arthritis Study, St. Albans City Hospital, St. Albans, UK
| | - Sam Norton
- Institute of Psychiatry, Psychology and Neuroscience, and Faculty of Life and Medical Science, King's College London, London, UK
| | - Lewis Carpenter
- Centre for Lifespan and Chronic Illness Research, University of Hertfordshire, Hatfield, UK
| | | | | | - Patrick Kiely
- St. Georges University Hospitals NHS Foundation Trust, London, UK
| | - Adam Young
- Early Rheumatoid Arthritis Study, St. Albans City Hospital, St. Albans, UK
| | | |
Collapse
|
31
|
Nieuwenhuis WP, de Wit MPT, Boonen A, van der Helm-van Mil AHM. Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the years 2010: earlier identification but more severe patient reported outcomes. Ann Rheum Dis 2016; 75:2054-2056. [DOI: 10.1136/annrheumdis-2016-209949] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 08/09/2016] [Indexed: 11/03/2022]
|
32
|
Carpenter L, Nikiphorou E, Sharpe R, Norton S, Rennie K, Bunn F, Scott DL, Dixey J, Young A. Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts. Rheumatology (Oxford) 2016; 55:1053-1065. [PMID: 26961746 DOI: 10.1093/rheumatology/kew004] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE To evaluate, firstly, all published data on baseline and annual progression rates of radiographic damage from all longitudinal observational cohorts, and secondly, the association of standard clinical and laboratory parameters with long-term radiographic joint damage. METHODS A comprehensive search of the literature from 1975 to 2014, using PubMed, SCOPUS and Cochrane databases, identified a total of 28 studies that investigated long-term radiographic progression, and 41 studies investigating predictors of long-term radiographic progression. This was submitted and approved by PROSPERO in February 2014 (Registration Number: CRD42014007589). RESULTS Meta-analysis indicated an overall baseline rate of 2.02%, and a yearly increase of 1.08% of maximum damage. Stratified analysis found that baseline radiographic scores did not differ significantly between cohorts recruiting patients pre- and post-1990 (2.01% vs 2.03%; P > 0.01); however, the annual rate of progression was significantly reduced in the post-1990 cohorts (0.68% vs 1.50%; P < 0.05). High levels of acute phase markers, baseline radiographic damage, anti-CCP and RF positivity remain consistently predictive of long-term radiographic joint damage. CONCLUSION Critical changes in treatment practices over the last three decades are likely to explain the reduction in the long-term progression of structural joint damage. Acute phase markers and presence of RF/anti-CCP are strongly associated with increased radiographic progression.
Collapse
Affiliation(s)
| | | | | | - Sam Norton
- Psychology Department, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London
| | | | - Frances Bunn
- Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield
| | - David L Scott
- Department of Rheumatology, Kings College London, London
| | - Josh Dixey
- Department of Rheumatology, New Cross Hospital, Wolverhampton and
| | - Adam Young
- Postgraduate Medicine, University of Hertfordshire, Hatfield, Rheumatology Department, St Albans City Hospital, St Albans, UK
| |
Collapse
|
33
|
Mian AN, Ibrahim F, Scott IC, Bahadur S, Filkova M, Pollard L, Steer S, Kingsley GH, Scott DL, Galloway J. Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies. BMC Musculoskelet Disord 2016; 17:44. [PMID: 26818465 PMCID: PMC4730644 DOI: 10.1186/s12891-016-0897-y] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 01/19/2016] [Indexed: 11/10/2022] Open
Abstract
Background Rheumatoid arthritis (RA) treatment paradigms have shifted over the last two decades. There has been increasing emphasis on combination disease modifying anti-rheumatic drug (DMARD) therapy, newer biologic therapies have become available and there is a greater focus on achieving remission. We have evaluated the impact of treatment changes on disease activity scores for 28 joints (DAS28) and disability measured by the health assessment questionnaire scores (HAQ). Methods Four cross-sectional surveys between 1996 and 2014 in two adjacent secondary care rheumatology departments in London evaluated changes in drug therapy, DAS28 and its component parts and HAQ scores (in three surveys). Descriptive statistics used means and standard deviations (SD) or medians and interquartile ranges (IQR) to summarise changes. Spearman’s correlations assessed relationships between assessments. Results 1324 patients were studied. Gender ratios, age and mean disease duration were similar across all cohorts. There were temporal increases in the use of any DMARDs (rising from 61 % to 87 % of patients from 1996-2014), combination DMARDs (1 % to 41 %) and biologic (0 to 32 %). Mean DAS28 fell (5.2 to 3.7), active disease (DAS28 > 5.1) declined (50 % to 18 %) and DAS28 remission (DAS28 < 2.6) increased (8 % to 28 %). In contrast HAQ scores were unchanged (1.30 to 1.32) and correlations between DAS28 and HAQ weakened (Spearman’s rho fell from 0.56 to 0.44). Conclusions Treatment intensity has increased over time, disease activity has fallen and there are more remissions. However, these improvements in controlling synovitis have not resulted in comparable reductions in disability measured by HAQ. As a consequence the relationship between DAS28 and HAQ has become weaker over time. Although the reasons for this divergence between disease activity and disability are uncertain, focussing treatment entirely in suppressing synovitis may be insufficient.
Collapse
Affiliation(s)
- Aneela N Mian
- Department of Rheumatology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. .,Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| | - Fowzia Ibrahim
- Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| | - Ian C Scott
- Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| | - Sardar Bahadur
- Department of Rheumatology, University Hospital Lewisham, London, SE13 6LH, UK.
| | - Maria Filkova
- Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| | - Louise Pollard
- Department of Rheumatology, University Hospital Lewisham, London, SE13 6LH, UK.
| | - Sophia Steer
- Department of Rheumatology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. .,Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| | - Gabrielle H Kingsley
- Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK. .,Department of Rheumatology, University Hospital Lewisham, London, SE13 6LH, UK.
| | - David L Scott
- Department of Rheumatology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. .,Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| | - James Galloway
- Department of Rheumatology, King's College Hospital, Denmark Hill, London, SE5 9RS, UK. .,Department of Rheumatology, King's College School of Medicine, King's College London, Weston Education Centre, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ, UK.
| |
Collapse
|
34
|
Pincus T, Chua JR, Gibson KA. Evidence from a Multidimensional Health Assessment Questionnaire (MDHAQ) of the Value of a Biopsychosocial Model to Complement a Traditional Biomedical Model in Care of Patients with Rheumatoid Arthritis. JOURNAL OF RHEUMATIC DISEASES 2016. [DOI: 10.4078/jrd.2016.23.4.212] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Theodore Pincus
- Division of Rheumatology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
| | - Jacquelin R Chua
- Division of Rheumatology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA
| | - Kathryn A Gibson
- Rheumatology Department, Liverpool Hospital, University of New South Wales, and Ingham Research Institute, Liverpool, NSW, Australia
| |
Collapse
|
35
|
Goodman SM, Johnson B, Zhang M, Huang WT, Zhu R, Figgie M, Alexiades M, Mandl LA. Patients with Rheumatoid Arthritis have Similar Excellent Outcomes after Total Knee Replacement Compared with Patients with Osteoarthritis. J Rheumatol 2015; 43:46-53. [PMID: 26628605 DOI: 10.3899/jrheum.150525] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/16/2015] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Although new treatments for rheumatoid arthritis (RA) are extremely effective in preventing disease progression, rates of total knee replacement (TKR) continue to rise. The ongoing need for TKR is problematic, especially as functional outcomes in patients with RA have been reported to be worse than in patients with osteoarthritis (OA). The purpose of this study is to assess pain, function, and quality of life 2 years after TKR in contemporary patients with RA compared with patients with OA. METHODS Primary TKR cases enrolled between May 1, 2007 and July 1, 2010 in a single institution TKR registry were eligible for this study. Validated RA cases were compared with OA at baseline and at 2 years. RESULTS We identified 4456 eligible TKR, including 136 RA. Compared with OA, RA TKR had significantly worse preoperative Western Ontario and McMaster Universities Osteoarthritis Index pain (55.9 vs 46.6, p < 0.0001) and function (58.7 vs 47.3, p < 0.0001); however, there were no differences at 2 years. Within RA, there was no difference for patients who were treated with biologic disease-modifying antirheumatic drugs versus those who did not in pain (p = 0.41) or function (p = 0.39) at 2 years. In a multivariate regression, controlling for multiple potential confounders, there was no independent association of RA with 2-year pain (p = 0.18) or function (p = 0.71). Satisfaction was high for both RA and OA. CONCLUSION Patients with RA undergoing primary TKR have excellent 2-year outcomes, comparable with OA, in spite of worse preoperative pain and function. In this contemporary cohort, RA is not an independent risk factor for poor outcomes.
Collapse
Affiliation(s)
- Susan M Goodman
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery.
| | - Beverly Johnson
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| | - Meng Zhang
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| | - Wei-Ti Huang
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| | - Rebecca Zhu
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| | - Mark Figgie
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| | - Michael Alexiades
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| | - Lisa A Mandl
- From the Division of Rheumatology, Weill Cornell Medical School, and Department of Medicine, and Department of Orthopedic Surgery, and Department of Biostatistics Core, Hospital for Special Surgery; Albert Einstein College of Medicine; Jacobi Medical Center, New York; North Central Bronx Hospital, Bronx, New York, USA.S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Department of Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center, and North Central Bronx Hospital; M. Zhang, PhD, Biostatistician, Hospital for Special Surgery; W.T. Huang, MS, Biostatistician, Hospital for Special Surgery; R. Zhu, BA, Research Assistant, Research and Rheumatology, Hospital for Special Surgery; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, Chief of Surgical Arthritis Service, Hospital for Special Surgery; M.M. Alexiades, MD, Associate Professor of Orthopedic Surgery, Weill Cornell Medicine College, and Associate Attending Physician, Hospital for Special Surgery; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Department of Rheumatology, Hospital for Special Surgery
| |
Collapse
|
36
|
Goodman SM, Figgie MA. Arthroplasty in patients with established rheumatoid arthritis (RA): Mitigating risks and optimizing outcomes. Best Pract Res Clin Rheumatol 2015; 29:628-42. [DOI: 10.1016/j.berh.2015.09.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
37
|
Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum 2015; 44:627-32. [DOI: 10.1016/j.semarthrit.2015.01.008] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Revised: 01/02/2015] [Accepted: 01/23/2015] [Indexed: 12/20/2022]
|
38
|
Goodman SM. Optimizing Perioperative Outcomes for Older Patients with Rheumatoid Arthritis Undergoing Arthroplasty: Emphasis on Medication Management. Drugs Aging 2015; 32:361-9. [DOI: 10.1007/s40266-015-0262-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
39
|
LoVerde ZJ, Mandl LA, Johnson BK, Figgie MP, Boettner F, Lee YY, Goodman SM. Rheumatoid Arthritis Does Not Increase Risk of Short-term Adverse Events after Total Knee Arthroplasty: A Retrospective Case-control Study. J Rheumatol 2015; 42:1123-30. [PMID: 25934825 DOI: 10.3899/jrheum.141251] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2015] [Indexed: 01/27/2023]
Abstract
OBJECTIVE More adverse events (AE) are reported after total knee arthroplasty (TKA) for patients with rheumatoid arthritis (RA) than for patients with osteoarthritis (OA). This study evaluates 6-month postoperative AE in a high-volume center in a contemporary RA cohort. METHODS Patients with RA in an institutional registry (2007-2010) were studied. AE were identified by self-report and review of office and hospital charts. Subjects with RA were matched to 2 with OA by age, sex, and procedure. RA-specific surgical volume was determined. Baseline characteristics and AE were compared and analyzed. RESULTS There were 159 RA TKA and 318 OA. Of the patients with RA, 88.0% were women, 24.5% received corticosteroids, 41.5% received biologics, and 67% received nonbiologic disease-modifying antirheumatic drugs (DMARD). There was no difference in comorbidities. RA-specific surgical volume was high; 64% of cases were performed by surgeons with ≥ 20 RA cases during the study period. Patients with RA had worse baseline pain and function and lower perceived health status (EQ-5D 0.59 vs 0.65, p < 0.01). There were no deep infections in either group and no difference in superficial infection (9.4% RA vs 10.1% OA, p = 0.82), myocardial infarction (0.7% RA vs 0% OA, p = 0.33), or thromboembolism (1.3% RA vs 0.6% OA, p = 0.60). CONCLUSION In a high-volume center, with high RA-specific experience, RA does not increase postoperative AE. Despite worse preoperative function and high steroid and DMARD use, complications were not increased. However, further study to determine generalizability is needed.
Collapse
Affiliation(s)
- Zachary J LoVerde
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery
| | - Lisa A Mandl
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery
| | - Beverly K Johnson
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery
| | - Mark P Figgie
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery
| | - Friedrich Boettner
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery
| | - Yuo-Yu Lee
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery
| | - Susan M Goodman
- From the Department of Internal Medicine, The Reading Hospital and Medical Center, Reading, Pennsylvania; Department of Rheumatology, Department of Orthopedic Surgery, and Research, Hospital for Special Surgery; Albert Einstein College of Medicine; Department of Rheumatology, Jacobi Medical Center; Weill Cornell College of Medicine, New York, New York; North Central Bronx Hospital, Bronx, New York, USA.Z.J. LoVerde, MD, PGY1 Resident, Internal Medicine, The Reading Hospital and Medical Center; L.A. Mandl, MD, MPH, Assistant Professor of Research Medicine, Assistant Professor of Public Health, Weill Cornell Medicine College, and Assistant Attending Physician, Rheumatology, Hospital for Special Surgery; B.K. Johnson, MD, MS, FACR, Assistant Professor of Medicine, Albert Einstein College of Medicine, and Director of Rheumatology, Jacobi Medical Center and the North Central Bronx Hospital; M.P. Figgie, MD, Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Attending Orthopedic Surgeon, and Chief of Surgical Arthritis Service, Hospital for Special Surgery; F. Boettner, MD, Assistant Professor of Orthopedic Surgery, Weill Cornell College of Medicine, and Assistant Attending Orthopedic Surgeon, Hospital for Special Surgery; Y. Lee, MS, Biostatistician, Hospital for Special Surgery; S.M. Goodman, MD, Associate Professor of Clinical Medicine, Weill Cornell Medicine College, and Associate Attending Physician, Rheumatology, Hospital for Special Surgery.
| |
Collapse
|
40
|
van Steenbergen HW, Tsonaka R, Huizinga TWJ, Boonen A, van der Helm-van Mil AHM. Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open 2015; 1:e000041. [PMID: 26509063 PMCID: PMC4612698 DOI: 10.1136/rmdopen-2014-000041] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 02/16/2015] [Accepted: 02/17/2015] [Indexed: 11/29/2022] Open
Abstract
Objective Fatigue is prevalent and disabling in rheumatoid arthritis (RA). Surprisingly, the long-term course of fatigue is studied seldom and it is unclear to what extent it is influenced by inflammation. This study aimed to determine the course of fatigue during 8 years follow-up, its association with the severity of inflammation and the effect of improved treatment strategies. Methods 626 patients with RA included in the Leiden Early Arthritis Clinic cohort were studied during 8 years. Fatigue severity, measured on a 0–100 mm scale, and other clinical variables were assessed yearly. Patients included in 1993–1995, 1996–1998 and 1999–2007 were treated with delayed treatment with disease-modifying antirheumatic drugs (DMARDs), early treatment with mild DMARDs and early treatment with methotrexate respectively. After multiple imputation, the serial measurements were analysed using linear quantile mixed models. Results Median fatigue severity at baseline was 45 mm and remained, despite treatment, rather stable thereafter. Female gender (effect size=4.4 mm), younger age (0.2 mm less fatigue/year), higher swollen and tender joint counts (0.3 mm and 1.0 mm more fatigue/swollen or tender joint) and C reactive protein-levels (0.1 mm more fatigue per mg/L) were independently and significantly (p<0.05) associated with fatigue severity over 8 years. Although improved treatment strategies associated with less severe radiographic progression, there was no effect on fatigue severity (p=0.96). Conclusions This largest longitudinal study on fatigue so far demonstrated that the association between inflammation and fatigue is statistically significant but effect sizes are small, suggesting that non-inflammatory pathways mediate fatigue as well. Improved treatment strategies did not result in less severe fatigue. Therefore, fatigue in RA remains an ‘unmet need’.
Collapse
Affiliation(s)
| | - Roula Tsonaka
- Department of Medical Statistics , Leiden University Medical Center , Leiden , The Netherlands
| | - Tom W J Huizinga
- Department of Rheumatology , Leiden University Medical Center , Leiden , The Netherlands
| | - Annelies Boonen
- Department of Rheumatology , University Hospital Maastricht , Maastricht , The Netherlands
| | | |
Collapse
|
41
|
Pincus T, Cutolo M. Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation 2015; 22:46-50. [PMID: 25227901 DOI: 10.1159/000362734] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Twelve clinical trials have documented that prednisone or prednisolone in doses of 10 mg/day or less is efficacious to improve function, maintain status and/or slow radiographic progression in patients with rheumatoid arthritis (RA). An early trial reported by de Andrade et al. [Ann Rheum Dis 1964;23:158-162] in 1964 indicated that 5 mg of prednisolone at night was preferred to 5 mg of prednisone in the morning. Harris et al. [J Rheumatol 1983;10:713-721] documented the efficacy of 5 mg/day of prednisone in a non-double-blind trial in 1983. Two important trials in the 1990s by Kirwan [N Engl J Med 1995;333:142-146] using 7.5 mg/day, and the COBRA study by Boers et al. [Lancet 1997;350:309-318] with step-down from 60 mg rapidly tapered to 5 mg/day led to strong advocacy of low-dose glucocorticoids. In 2002, the first Utrecht Study [Ann Intern Med 2002;136:1-12] indicated that 10 mg/day prednisone slowed radiographic progression, a finding confirmed and extended in 2005 by Svensson et al. [Arthritis Rheum 2005;52:3360-3370] with 7.5 mg/day, and Wassenberg et al. [Arthritis Rheum 2005;52:3371-3380] with 5 mg/day of prednisolone. In 2008, Buttgereit et al. [Lancet 2008;371:205-214] reported CAPRA-1, which documented that modified-release prednisone or prednisolone taken at bedtime led to lower morning stiffness and IL-6 levels compared to usual morning prednisone. In 2009, Pincus et al. [Ann Rheum Dis 2009;68:1715-1720] reported a withdrawal clinical trial, in which patients who took 3 mg/day were gradually withdrawn to placebo, and dropped out at a significantly higher rate than control patients who were 'withdrawn' to prednisone. In 2012, a second Utrecht Study [Ann Intern Med 2012;156:329-339], CAMERA-II, documented that 10 mg of prednisone added to a 'treat-to-target' strategy with methotrexate provided incremental slowing of radiographic progression. An Italian study of patients with early RA who received step-up disease-modifying antirheumatic drug therapy over 2 years plus prednisolone or not indicated higher rates of clinical remission and sustained remission associated with 7.5 mg/day of prednisolone [Arthritis Res Ther 2012; 14:R112]. The CAPRA-2 trial [Ann Rheum Dis 2013;72:204-210] documented that modified-release nighttime prednisone or prednisolone was significantly more efficacious than placebo. Taken together, these 12 clinical trials indicate that low-dose glucocorticoids prednisone or prednisolone provides symptomatic relief, improved functional status and slowing of radiographic progression for patients with RA. © 2014 S. Karger AG, Basel.
Collapse
|
42
|
Caporali R, Todoerti M, Scirè CA, Montecucco C, Cutolo M. Oral low-dose glucocorticoids should be included in any recommendation for the use of non-biologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. Neuroimmunomodulation 2015; 22:104-11. [PMID: 25227117 DOI: 10.1159/000362730] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
At present, growing scientific evidence from the medical literature and expert opinion provides strong consideration for a mandatory role of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). Earlier application strategies were based on initial high doses, with subsequent tapering schedules, resulting in dose-related side effects. Recent low-dose GC schemes are more feasible in routine care, while providing evidence of clinical, functional and structural efficacy. Thus, initial low-dose GC 'bridging' treatment on a disease-modifying antirheumatic drug background should be included in any existing recommendations for RA management, as very recently advocated by the EULAR Task Force 2013 updated guidelines. Long-term low-dose therapy appears to provide acceptable safety, leading to long-standing slowing of structural damage, seen even after GC therapy withdrawal. Gaps in knowledge about the optimal method to taper and possibly discontinue GC treatment remain, and this topic should be addressed in clinical trials and observational studies. Recent efforts in GC medication have also included the introduction of a modified-release drug formulation capable of drug delivery consistent with chronobiological pathogenetic rhythms of disease, which has been quite efficacious in controlling the signs and symptoms related to pathways of circadian cytokines. Long-term data will further clarify the add-on benefits of such modified-release formulations.
Collapse
Affiliation(s)
- Roberto Caporali
- Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
| | | | | | | | | |
Collapse
|
43
|
Pincus T, Sokka T, Cutolo M. The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation 2015; 22:89-103. [PMID: 25228430 DOI: 10.1159/000362735] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Quantitative observations are presented concerning treatment with glucocorticoids of 308 patients with rheumatoid arthritis (RA) at a weekly academic rheumatology setting over 25 years from 1980 to 2004. A database of all visits included medications and multidimensional health assessment questionnaire scores for physical function, pain and routine assessment of patient index data (RAPID3; and a surrogate RAPID3-EST), completed by each patient at each visit in routine care. Over the 5-year periods of 1980-1984, 1985-1989, 1990-1994, 1995-1999 and 2000-2004, the mean initial prednisone daily dose declined from 10.3 to 6.5, 5.1, 4.1 and 3.6 mg/day, as initial doses were >5 mg/day in 49, 16, 7, 7 and 3% of patients, 5 mg/day in 51, 80, 70, 26 and 10%, and <5 mg/day in 0, 4, 23, 67 and 86%. Reduction of prednisone doses in the respective five-year periods was accompanied by increased and earlier use of methotrexate as the first disease-modifying antirheumatic drug (DMARD) in 10, 26, 57, 71 and 78%, and methotrexate treatment in 10, 26, 74, 82 and 92% of patients within the first year of disease. Higher methotrexate doses in the respective five-year periods were used after 1990, along with lower prednisone doses. Most patients were treated indefinitely with both low-dose prednisone and methotrexate; 80% continued both medications for more than 5 years. The primary adverse events were skin-thinning and bruising. New hypertension, diabetes and cataracts were seen in fewer than 10% of patients. While efficacy and safety cannot be analyzed definitively from observational data, the data suggest that many patients with RA might be treated effectively with weekly low-dose methotrexate along with initial and long-term, low-dose prednisone of <5 mg/day.
Collapse
|
44
|
Uutela T, Kautiainen H, Järvenpää S, Salomaa S, Hakala M, Häkkinen A. Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s. Scand J Rheumatol 2014; 44:173-81. [PMID: 25438985 DOI: 10.3109/03009742.2014.957240] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Better treatment strategies and therapeutic options have changed the treatment of rheumatoid arthritis (RA) during the past decade. Our objective was to examine clinical and patient-reported outcomes in patients with RA treated in 1998-99 and 2011-12. METHOD The cross-sectional observational study included 303 consecutive outpatients (n = 103 in 1998-99 and n = 200 in 2011-12) from the same outpatient clinic. Patient questionnaires included patients' sociodemographics, the Health Assessment Questionnaire (HAQ) for functional ability, the Nottingham Health Profile (NHP) for health-related quality of life (HRQoL), self-reported general health (GH), and operations performed due to RA. A clinical examination was conducted for all patients. Comorbidities according to the Charlson Comorbidity Index (CCI), anti-rheumatic drugs and medications were recorded and the HAQ and NHP dimensions calculated. The results from these two patient cohorts were compared. RESULTS The cohorts were comparable with regard to age, sex, and RA duration while the patients in the 2011-12 cohort were less often seropositive for rheumatoid factor (RF), had a better socioeconomic situation, better functional and working ability, and a decreased rate of RA surgery. The patients in 2011-12 had higher comorbidities and poorer GH while the HRQoL dimensions did not differ between the cohorts except for better mobility in 2011-12. Methotrexate (MTX) and combinations of conventional anti-rheumatic drugs were more frequently used in 2011-12. Biologicals were used only in 2011-12. CONCLUSIONS According to our results, more active anti-rheumatic therapy coincides with better RA-related outcomes. However, the result was the opposite with regard to overall health and comorbidities. Is this a new challenge in the treatment RA?
Collapse
Affiliation(s)
- T Uutela
- Department of Medicine, Central Hospital of Lapland , Rovaniemi , Finland
| | | | | | | | | | | |
Collapse
|
45
|
Goodman SM, Ravi B, Hawker G. Outcomes in rheumatoid arthritis patients undergoing total joint arthroplasty. ACTA ACUST UNITED AC 2014. [DOI: 10.2217/ijr.14.47] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
46
|
Nikiphorou E, Konan S, MacGregor AJ, Haddad FS, Young A. The surgical treatment of rheumatoid arthritis: a new era? Bone Joint J 2014; 96-B:1287-9. [PMID: 25274910 DOI: 10.1302/0301-620x.96b10.34506] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
There has been an in increase in the availability of effective biological agents for the treatment of rheumatoid arthritis as well as a shift towards early diagnosis and management of the inflammatory process. This article explores the impact this may have on the place of orthopaedic surgery in the management of patients with rheumatoid arthritis.
Collapse
Affiliation(s)
- E Nikiphorou
- University of Hertfordshire, College Lane, Hatfield, Hertfordshire AL10 9AB, UK
| | - S Konan
- University College London Hospitals, Euston Road, London, NW1 2BU, UK
| | - A J MacGregor
- University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
| | - F S Haddad
- University College London Hospitals, Euston Road, London, NW1 2BU, UK
| | - A Young
- University of Hertfordshire, College Lane, Hatfield, Hertfordshire AL10 9AB, UK
| |
Collapse
|
47
|
Pedersen JK, Lorenzen T, Ejbjerg B, Szkudlarek M, Voss A, Østergaard M, Svendsen AJ, Andersen LS, Hørslev-Petersen K. Low-field magnetic resonance imaging or combined ultrasonography and anti-cyclic citrullinated peptide antibody improve correct classification of individuals as established rheumatoid arthritis: results of a population-based, cross-sectional study. BMC Musculoskelet Disord 2014; 15:268. [PMID: 25103610 PMCID: PMC4132194 DOI: 10.1186/1471-2474-15-268] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Accepted: 07/28/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The aim of the present study was to evaluate the accuracy of two approaches using magnetic resonance imaging (MRI) or combined ultrasonography (US) and anti-cyclic citrullinated peptide antibody (ACPA) for diagnosis and classification of individuals with established rheumatoid arthritis (RA). METHODS In 53 individuals from a population-based, cross-sectional study, historic fulfilment of the American College of Rheumatology (ACR) 1987 criteria ("classification") or RA diagnosed by a rheumatologist ("diagnosis") were used as standard references. The sensitivity, specificity and Area under Curve for Receiver Operating Characteristics curves (ROC-area: (sensitivity + specificity)/2) were calculated for "current fulfilment of the ACR 1987 criteria" (list format), "adapted ACR 1987 criteria" (list format, substituting IgM rheumatoid factor with ACPA and clinical joint swelling and erosions on radiography with synovitis and erosions detected by US on a semi-quantitative scale), and RA MRI scoring System (RAMRIS) scores on low-field MRI in the unilateral hand. RESULTS For the ACR 1987 criteria the ROC-area was 75% (sensitivity/specificity = 50%/100%) (with "classification" as standard reference) and 69% (44%/94%) (with "diagnosis" as standard reference), while for the adapted ACR 1987 criteria it was 86% (75%/97%) (classification) and 82% (72%/91%) (diagnosis). For RAMRIS synovitis score in metacarpophalangeal (MCP) joints only (cut-off ≥5), the ROC-area (sensitivity/specificity) was 78% (62%/94%) (classification) and 85% (69%/100%) (diagnosis), while for the total synovitis score of MCP joints plus wrist (cut-off ≥10) it was 78% (62%/94%) (both classification and diagnosis). CONCLUSIONS Compared with the ACR 1987 criteria, low-field MRI alone or adapted criteria incorporating US and ACPA increased the correct classification and diagnosis of RA.
Collapse
Affiliation(s)
- Jens K Pedersen
- King Christian 10th Hospital for Rheumatic Diseases, South Jutland Hospital, Toldbodgade 3, 6300 Graasten, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Goodman SM, Ramsden-Stein DN, Huang WT, Zhu R, Figgie MP, Alexiades MM, Mandl LA. Patients with Rheumatoid Arthritis Are More Likely to Have Pain and Poor Function After Total Hip Replacements than Patients with Osteoarthritis. J Rheumatol 2014; 41:1774-80. [DOI: 10.3899/jrheum.140011] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Objective.Total hip replacement (THR) outcomes have been worse for patients with rheumatoid arthritis (RA) compared with those who have osteoarthritis (OA). Whether this remains true in contemporary patients with RA with a high use of disease-modifying and biologic therapy is unknown. The purpose of our study is to assess pain, function, and quality of life 2 years after primary THR, comparing patients with RA and patients with OA.Methods.Baseline and 2-year data were compared between validated patients with RA and patients with OA who were enrolled in a single-center THR registry between May 1, 2007, and February 25, 2011.Results.There were 5666 eligible primary THR identified, of which 193 were for RA. RA THR had worse baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain (44.8 vs 53.2, p < 0.001) and function (38.7 vs 49.9, p < 0.001) compared with OA. These differences remained after surgery: pain (88.4 vs 94.0, p < 0.001) and function (82.9 vs 91.8, p < 0.001). Patients with RA were as likely to have a significant improvement as patients with OA (Δ WOMAC > 10) in pain (94% vs 96%, p = 0.35) and function (95% vs 94%, p = 0.69), but were 4 times as likely to have worse function (WOMAC ≤ 60; 19% vs 4%, p < 0.001) and pain (12% vs 3%, p < 0.001). In multivariate logistic regression controlling for multiple potential confounders, RA increased the odds of poor postoperative function (OR 4.32, 95% CI 1.57–11.9), and in patients without a previous primary THR, worse postoperative pain (OR 3.17, 95% CI 1.06–9.53).Conclusion.Contemporary patients with RA have significant improvements in pain and function after THR, but higher proportions have worse 2-year pain and function. In addition, RA is an independent predictor of 2-year pain and poor function after THR, despite high use of disease-modifying therapy.
Collapse
|
49
|
Goodman SM, Mandl LA, Figgie M, Johnson BK, Alexiades M, Ghomrawi H. The use of biologic DMARDs identifies rheumatoid arthritis patients with more optimistic expectations of total knee arthroplasty. HSS J 2014; 10:117-23. [PMID: 25050094 PMCID: PMC4071470 DOI: 10.1007/s11420-014-9380-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 01/06/2014] [Indexed: 02/07/2023]
Abstract
BACKGROUND Preoperative expectations of total knee arthroplasty (TKA) correlate with postsurgical satisfaction, and are linked to outcomes. Rheumatoid arthritis (RA), and other chronic diseases, may lower expectations, although new biologic medications have greatly enhanced patients' quality of life. QUESTIONS/PURPOSES The purpose of this study is to compare preoperative expectations of RA to those of matched osteoarthritis (OA) patients undergoing TKA, and examine the subset of RA on biologic DMARD therapy. METHODS For a cross-sectional study, RA and OA identified from an institutional TKA registry were matched on age, sex, prior TKA, and preoperative function. Expectations were measured using the Hospital for Special Surgery (HSS) Knee Expectations Survey. Expectations and quality of life measures were assessed preoperatively and scores were compared between RA and OA. RESULTS One hundred fourteen RA cases, 46.5% on biologics, were matched to 228 OA cases. The average expectations score was not significantly lower for RA compared to OA (72.9 ± 20.7 vs. 77.2 ± 18.3, p = 0.040. RA on biologics had expectations similar to OA (total expectation score 76.3 ± 18.1 vs. 77.4 ± 17.4, p = 0.71), while RA not on biologics had expectations that were significantly lower (69.9 ± 22.4 vs. 77.1 ± 19.0, p = 0.03). CONCLUSION Use of biologics in RA patients was associated with higher expectations, similar to those of OA patients, but the effect on outcomes is not known. Further studies should assess the effect of higher expectations in RA patients on outcomes.
Collapse
Affiliation(s)
- Susan M. Goodman
- />Division of Rheumatology, Weill Cornell Medical College, New York, NY 10065 USA
- />Division of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021 USA
| | - Lisa A. Mandl
- />Division of Rheumatology, Weill Cornell Medical College, New York, NY 10065 USA
- />Division of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021 USA
| | - Mark Figgie
- />Department of Orthopedic Surgery, Weill Cornell Medical College, New York, NY 10065 USA
- />Department of Orthopedic Surgery, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021 USA
| | - Beverly K. Johnson
- />Division of Rheumatology, Weill Cornell Medical College, New York, NY 10065 USA
- />Division of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021 USA
| | - Michael Alexiades
- />Department of Orthopedic Surgery, Weill Cornell Medical College, New York, NY 10065 USA
- />Department of Orthopedic Surgery, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021 USA
| | - Hassan Ghomrawi
- />Division of Health Policy, Weill Cornell Medical College, New York, NY USA
- />Hospital for Special Surgery, 535 East 70th Street, New York, NY USA
| |
Collapse
|
50
|
Diffin JG, Lunt M, Marshall T, Chipping JR, Symmons DPM, Verstappen SMM. Has the severity of rheumatoid arthritis at presentation diminished over time? J Rheumatol 2014; 41:1590-9. [PMID: 24986850 DOI: 10.3899/jrheum.131136] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE To examine the pattern of disease severity in patients with rheumatoid arthritis (RA) at presentation to the Norfolk Arthritis Register (NOAR) over 20 years. METHODS NOAR is a primary-care-based cohort of patients with recent-onset inflammatory polyarthritis. At baseline, subjects are assessed and examined by a research nurse. The Health Assessment Questionnaire (HAQ) is administered and the DAS28 (28-joint Disease Activity Score) is calculated. Information is collected on disease-modifying antirheumatic drug exposure. In this study, patients (symptom duration of < 2 years at baseline) were grouped into 4 cohorts (Cohort 1: 1990-1994; Cohort 2: 1995-1999; Cohort 3: 2000-2004; Cohort 4: 2005-2008). The American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria for RA were applied retrospectively at baseline. Regression analyses were used to examine whether calendar year of presentation to NOAR was associated with baseline HAQ and DAS28 scores. Potential confounders included age at symptom onset, sex, rheumatoid factor, and anticyclic citrullinated peptide antibody positivity. RESULTS A total of 1724 patients met the ACR/EULAR 2010 RA criteria at baseline. Unadjusted mean DAS28 scores decreased over time. Calendar year of presentation to NOAR was significantly associated with lower DAS28 scores over time [Y = 4.51 + (-0.56 × year) + (0.44 × year(2))]. Although unadjusted median HAQ scores increased over time, calendar year of presentation to NOAR was not significantly associated with HAQ scores [Y = (1.1) + (0.023 × year) + (0.05 × year(2))]. Similar results were observed in each subpopulation of patients. CONCLUSION While baseline disease activity has lessened slightly over time, there has been no improvement in baseline levels of functional disability.
Collapse
Affiliation(s)
- Janet G Diffin
- From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester, Manchester; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich; Norfolk Arthritis Register (NOAR), School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust and University of Manchester Partnership, Manchester, UK.J.G. Diffin, PhD, Research Associate, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester; M. Lunt, PhD, Reader in Medical Statistics, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester; T. Marshall, MD, Consultant Rheumatologist, Department of Rheumatology, Norfolk and Norwich University Hospital; J.R. Chipping, NOAR Deputy Clinical Manager, School of Medicine, Health Policy, and Practice, University of East Anglia; D.P.M. Symmons, MD, FRCP, FFPH, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership; S.M.M. Verstappen, PhD, Senior Research Fellow, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester
| | - Mark Lunt
- From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester, Manchester; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich; Norfolk Arthritis Register (NOAR), School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust and University of Manchester Partnership, Manchester, UK.J.G. Diffin, PhD, Research Associate, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester; M. Lunt, PhD, Reader in Medical Statistics, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester; T. Marshall, MD, Consultant Rheumatologist, Department of Rheumatology, Norfolk and Norwich University Hospital; J.R. Chipping, NOAR Deputy Clinical Manager, School of Medicine, Health Policy, and Practice, University of East Anglia; D.P.M. Symmons, MD, FRCP, FFPH, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership; S.M.M. Verstappen, PhD, Senior Research Fellow, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester
| | - Tarnya Marshall
- From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester, Manchester; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich; Norfolk Arthritis Register (NOAR), School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust and University of Manchester Partnership, Manchester, UK.J.G. Diffin, PhD, Research Associate, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester; M. Lunt, PhD, Reader in Medical Statistics, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester; T. Marshall, MD, Consultant Rheumatologist, Department of Rheumatology, Norfolk and Norwich University Hospital; J.R. Chipping, NOAR Deputy Clinical Manager, School of Medicine, Health Policy, and Practice, University of East Anglia; D.P.M. Symmons, MD, FRCP, FFPH, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership; S.M.M. Verstappen, PhD, Senior Research Fellow, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester
| | - Jacqueline R Chipping
- From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester, Manchester; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich; Norfolk Arthritis Register (NOAR), School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust and University of Manchester Partnership, Manchester, UK.J.G. Diffin, PhD, Research Associate, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester; M. Lunt, PhD, Reader in Medical Statistics, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester; T. Marshall, MD, Consultant Rheumatologist, Department of Rheumatology, Norfolk and Norwich University Hospital; J.R. Chipping, NOAR Deputy Clinical Manager, School of Medicine, Health Policy, and Practice, University of East Anglia; D.P.M. Symmons, MD, FRCP, FFPH, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership; S.M.M. Verstappen, PhD, Senior Research Fellow, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester
| | - Deborah P M Symmons
- From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester, Manchester; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich; Norfolk Arthritis Register (NOAR), School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust and University of Manchester Partnership, Manchester, UK.J.G. Diffin, PhD, Research Associate, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester; M. Lunt, PhD, Reader in Medical Statistics, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester; T. Marshall, MD, Consultant Rheumatologist, Department of Rheumatology, Norfolk and Norwich University Hospital; J.R. Chipping, NOAR Deputy Clinical Manager, School of Medicine, Health Policy, and Practice, University of East Anglia; D.P.M. Symmons, MD, FRCP, FFPH, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership; S.M.M. Verstappen, PhD, Senior Research Fellow, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester
| | - Suzanne M M Verstappen
- From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester, Manchester; Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich; Norfolk Arthritis Register (NOAR), School of Medicine, Health Policy, and Practice, University of East Anglia, Norwich; UK National Institute for Health Research (NIHR) Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals National Health Service (NHS) Foundation Trust and University of Manchester Partnership, Manchester, UK.J.G. Diffin, PhD, Research Associate, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, and The School of Nursing, Midwifery, and Social Work, University of Manchester; M. Lunt, PhD, Reader in Medical Statistics, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester; T. Marshall, MD, Consultant Rheumatologist, Department of Rheumatology, Norfolk and Norwich University Hospital; J.R. Chipping, NOAR Deputy Clinical Manager, School of Medicine, Health Policy, and Practice, University of East Anglia; D.P.M. Symmons, MD, FRCP, FFPH, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership; S.M.M. Verstappen, PhD, Senior Research Fellow, Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester.
| |
Collapse
|